{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T08:59:38Z","timestamp":1781254778737,"version":"3.54.1"},"reference-count":592,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Talanta"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.talanta.2025.129132","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T02:33:34Z","timestamp":1763692414000},"page":"129132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Molecular targeted therapies, omics, and AI based theranostics approaches for the treatment of prostate cancer"],"prefix":"10.1016","volume":"300","author":[{"given":"Shifa","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanshu","family":"Nema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varsha","family":"Kashaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushil K.","family":"Kashaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.talanta.2025.129132_bib1","first-page":"95","article-title":"Omics sciences and precision medicine in prostate cancer","volume":"174","author":"Medori","year":"2023","journal-title":"La Clinica terapeutica"},{"issue":"4","key":"10.1016\/j.talanta.2025.129132_bib2","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.soncn.2011.07.002","article-title":"Prostate cancer overview","volume":"27","author":"Dunn","year":"2011","journal-title":"Semin. Oncol. Nurs."},{"key":"10.1016\/j.talanta.2025.129132_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.1885","article-title":"Exosome proteomic analyses identify inflammatory phenotype and novel biomarkers in African American prostate cancer patients","author":"Panigrahi","year":"2019","journal-title":"Cancer Med."},{"issue":"17","key":"10.1016\/j.talanta.2025.129132_bib4","doi-asserted-by":"crossref","first-page":"5730","DOI":"10.3390\/molecules27175730","article-title":"Prostate cancer review: genetics, diagnosis, treatment options, and alternative approaches","volume":"27","author":"Sekhoacha","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.talanta.2025.129132_bib5","unstructured":"Chen J., Zhang D., Yan W., Yang D., Shen B. Translational bioinformatics for diagnostic and prognostic prediction of prostate cancer in the next-generation sequencing era. BioMed Res. Int.."},{"issue":"1","key":"10.1016\/j.talanta.2025.129132_bib6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41572-020-00243-0","article-title":"Prostate cancer","volume":"7","author":"Rebello","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.talanta.2025.129132_bib7","first-page":"70","volume":"387","author":"Attard","year":"2016","journal-title":"Prostate cancer. Lancet"},{"issue":"1","key":"10.1016\/j.talanta.2025.129132_bib8","first-page":"15","article-title":"Radiologic anatomy of the prostate gland: a clinical approach","volume":"38","author":"Coakley","year":"2000","journal-title":"Radiol. Clin."},{"key":"10.1016\/j.talanta.2025.129132_bib9","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/pros.2990020105","article-title":"The zonal anatomy of the prostate","volume":"2","author":"McNeal","year":"1981","journal-title":"Prostate"},{"key":"10.1016\/j.talanta.2025.129132_bib10","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1432-0436.2008.00278.x","article-title":"Prostate development: a historical perspective","volume":"76","author":"Timms","year":"2008","journal-title":"Differentiation"},{"key":"10.1016\/j.talanta.2025.129132_bib11","first-page":"11","article-title":"Normal and pathologic anatomy of prostate","volume":"17","author":"McNeal","year":"1981","journal-title":"Urology"},{"key":"10.1016\/j.talanta.2025.129132_bib12","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/jnci\/djt151","article-title":"Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men","volume":"105","author":"Zlotta","year":"2013","journal-title":"J. Natl Cancer Inst."},{"key":"10.1016\/j.talanta.2025.129132_bib13","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3390\/biom9040131","article-title":"Splicing factors have an essential role in prostate cancer progression and androgen receptor signaling","volume":"9","author":"Takayama","year":"2019","journal-title":"Biomolecules"},{"issue":"6","key":"10.1016\/j.talanta.2025.129132_bib14","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.talanta.2025.129132_bib15","unstructured":"Ferlay J EM, Lam F, Colombet M, Mery L, Pineros M, Znaor A, Soerjomataram I, et al. Global cancer observatory: cancer today. Lyon, France: International Agency for Research on Cancer. Available from: https:\/\/gco.iarc.fr\/today, Accessed 02 February 2019."},{"issue":"6","key":"10.1016\/j.talanta.2025.129132_bib16","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1093\/jnci\/djp001","article-title":"Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context","volume":"101","author":"Draisma","year":"2009","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.talanta.2025.129132_bib17","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/bjc.2011.273","article-title":"Ethnic differences in prostate cancer","volume":"105","author":"Kheirandish","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.talanta.2025.129132_bib18","series-title":"Prostate Cancer","first-page":"17","article-title":"The etiology of prostate cancer","author":"Lim Ng","year":"2021"},{"issue":"8","key":"10.1016\/j.talanta.2025.129132_bib19","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1111\/j.1464-410X.2004.04795.x","article-title":"Diet, anthropometric measures and prostate cancer risk: a review of prospective cohort and intervention studies","volume":"93","author":"Dagnelie","year":"2004","journal-title":"BJU Int."},{"issue":"7","key":"10.1016\/j.talanta.2025.129132_bib20","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nrc1389","article-title":"The multiethnic cohort study: exploring genes, lifestyle and cancer risk","volume":"4","author":"Kolonel","year":"2004","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.talanta.2025.129132_bib21","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/oxfordjournals.epirev.a000798","article-title":"Fat, meat, and prostate cancer","volume":"23","author":"Kolonel","year":"2001","journal-title":"Epidemiol. Rev."},{"issue":"3","key":"10.1016\/j.talanta.2025.129132_bib22","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1080\/02841860510029572","article-title":"Diet, lifestyle and risk of prostate cancer","volume":"44","author":"Wolk","year":"2005","journal-title":"Acta Oncol"},{"issue":"3","key":"10.1016\/j.talanta.2025.129132_bib23","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/aja.2011.142","article-title":"Lifestyle and dietary factors in the prevention of lethal prostate cancer","volume":"14","author":"Wilson","year":"2012","journal-title":"Asian J. Androl."},{"key":"10.1016\/j.talanta.2025.129132_bib24","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejca.2016.09.026","article-title":"Diet, body size, physical activity and risk of prostate cancer: an umbrella review of the evidence","volume":"69","author":"Markozannes","year":"2016","journal-title":"Eur. J. Cancer"},{"issue":"7","key":"10.1016\/j.talanta.2025.129132_bib25","first-page":"807","article-title":"Prostate cancer: 3. Individual risk factors","volume":"159","author":"Gallagher","year":"1998","journal-title":"CMAJ (Can. Med. Assoc. J.)"},{"key":"10.1016\/j.talanta.2025.129132_bib26","series-title":"Prostate Cancer","year":"2002"},{"issue":"5","key":"10.1016\/j.talanta.2025.129132_bib27","first-page":"282","article-title":"[constitutional risk factors in prostate cancer]","volume":"35","author":"Ferris-i-Tortajada","year":"2011","journal-title":"Actas Urol. Esp."},{"key":"10.1016\/j.talanta.2025.129132_bib28","first-page":"45","article-title":"Association between family history of prostate cancer","volume":"7","author":"Sridhar","year":"2010","journal-title":"JMH"},{"issue":"3","key":"10.1016\/j.talanta.2025.129132_bib29","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1136\/jmg.40.3.e21","article-title":"RNASEL mutations in hereditary prostate cancer","volume":"40","author":"Chen","year":"2003","journal-title":"J. Med. Genet."},{"issue":"7155","key":"10.1016\/j.talanta.2025.129132_bib30","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/nature06042","article-title":"Small self-RNA generated by RNase L amplifies antiviral innate immunity","volume":"448","author":"Malathi","year":"2007","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.talanta.2025.129132_bib31","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1086\/344516","article-title":"Meta-analysis of associations of the Ser217Leu and Ala541Thr variants in ELAC2 (HPC2) and prostate cancer","volume":"71","author":"Camp","year":"2002","journal-title":"Am. J. Hum. Genet."},{"issue":"41","key":"10.1016\/j.talanta.2025.129132_bib32","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1038\/sj.onc.1209571","article-title":"ELAC2, a putative prostate cancer susceptibility gene product, potentiates TGF-beta\/Smad-induced growth arrest of prostate cells","volume":"25","author":"Noda","year":"2006","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.talanta.2025.129132_bib33","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/ng994","article-title":"Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk","volume":"32","author":"Xu","year":"2002","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.talanta.2025.129132_bib34","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/humu.20271","article-title":"Germline mutations of the MSR1 gene in prostate cancer families from Germany","volume":"27","author":"Maier","year":"2006","journal-title":"Hum. Mutat."},{"issue":"2","key":"10.1016\/j.talanta.2025.129132_bib35","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/ng1239","article-title":"No association of germline alteration of MSR1 with prostate cancer risk","volume":"35","author":"Wang","year":"2003","journal-title":"Nat. Genet."},{"issue":"2","key":"10.1016\/j.talanta.2025.129132_bib36","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/2477","article-title":"Evidence for a prostate cancer susceptibility locus on the X chromosome","volume":"20","author":"Xu","year":"1998","journal-title":"Nat. Genet."},{"issue":"4","key":"10.1016\/j.talanta.2025.129132_bib37","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s004390000384","article-title":"Analysis of HPC1, HPCX, and PCaP in Icelandic hereditary prostate cancer","volume":"107","author":"Bergthorsson","year":"2000","journal-title":"Hum. Genet."},{"issue":"10","key":"10.1016\/j.talanta.2025.129132_bib38","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1093\/hmg\/ddp100","article-title":"Dense genomewide SNP linkage scan in 301 hereditary prostate cancer families identifies multiple regions with suggestive evidence for linkage","volume":"18","author":"Stanford","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.talanta.2025.129132_bib39","first-page":"273","article-title":"Epidemiology of prostate can cer","volume":"47","author":"Haas","year":"1997","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.talanta.2025.129132_bib40","series-title":"Cancer Facts & Figures 2003","year":"2003"},{"key":"10.1016\/j.talanta.2025.129132_bib41","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/S0022-5347(17)40078-4","article-title":"Clinical evidence for and implications of the multistep development of prostate cancer","volume":"143","author":"Carter","year":"1990","journal-title":"J. Urol."},{"key":"10.1016\/j.talanta.2025.129132_bib42","series-title":"Clinical Oncology","first-page":"1823","article-title":"Prostate cancer","author":"Scher","year":"2000"},{"issue":"13","key":"10.1016\/j.talanta.2025.129132_bib43","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1002\/cncr.27941","article-title":"Agent Orange as a risk factor for high-grade prostate cancer","volume":"119","author":"Ansbaugh","year":"2013","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.talanta.2025.129132_bib44","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1002\/cncr.23696","article-title":"Editorial comment on: agent Orange exposure, Vietnam war veterans, and the risk of prostate cancer","volume":"113","author":"Shah","year":"2008","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.talanta.2025.129132_bib45","doi-asserted-by":"crossref","first-page":"6641","DOI":"10.1073\/pnas.76.12.6641","article-title":"Estrogenic activity of the insecticide chlordecone (Kepone) and interaction with uterine estrogen receptors","volume":"76","author":"Hammond","year":"1979","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"5\u20136","key":"10.1016\/j.talanta.2025.129132_bib46","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1080\/15287398109530109","article-title":"Estrogenic activity of the insecticide chlordecone in the reproductive tract of birds and mammals","volume":"8","author":"Eroschenko","year":"1981","journal-title":"J. Toxicol. Environ. Health"},{"issue":"6","key":"10.1016\/j.talanta.2025.129132_bib47","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1093\/carcin\/10.6.1047","article-title":"Evaluation of chlordecone in a two stage model of hepatocarcinogenesis: a significant sex difference in the hepatocellular carcinoma incidence","volume":"10","author":"Sirica","year":"1989","journal-title":"Carcinogenesis"},{"issue":"9","key":"10.1016\/j.talanta.2025.129132_bib48","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/aje\/kwg040","article-title":"Use of agricultural pesticides and prostate cancer risk in the agricultural health study cohort","volume":"157","author":"Alavanja","year":"2003","journal-title":"Am. J. Epidemiol."},{"issue":"8","key":"10.1016\/j.talanta.2025.129132_bib49","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1289\/ehp.8911","article-title":"Phor ate exposure and incidence of cancer in the agricultural health study","volume":"114","author":"Mahajan","year":"2006","journal-title":"Environ. Health Perspect."},{"issue":"7","key":"10.1016\/j.talanta.2025.129132_bib50","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.envres.2009.06.006","article-title":"Cancer incidence among pesticide applicators exposed to butylate in the Agricultural health study (AHS)","volume":"109","author":"Lynch","year":"2009","journal-title":"Environ. Res."},{"issue":"1","key":"10.1016\/j.talanta.2025.129132_bib51","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1289\/ehp.0800446","article-title":"Coumaphos exposure and incident cancer among male participants in the agri cultural health study (AHS)","volume":"118","author":"Christensen","year":"2010","journal-title":"Environ. Health Perspect."},{"issue":"27","key":"10.1016\/j.talanta.2025.129132_bib52","doi-asserted-by":"crossref","first-page":"12624","DOI":"10.1016\/S0021-9258(18)67136-4","article-title":"Purification and characterization of chlordecone reductase from human liver","volume":"261","author":"Molowa","year":"1986","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.talanta.2025.129132_bib53","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1097\/00008571-199912000-00011","article-title":"Characterization of a novel variant (S145C\/L311V) of 3alpha-hydroxysteroid\/dihydrodiol dehydrogenase in human liver","volume":"9","author":"Kume","year":"1999","journal-title":"Pharmacogenetics"},{"issue":"1\u20132","key":"10.1016\/j.talanta.2025.129132_bib54","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jsbmb.2011.05.002","article-title":"Bisphenol A: an endocrine disruptor with widespread exposure and multiple effects","volume":"127","author":"Rubin","year":"2011","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.talanta.2025.129132_bib55","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.foodchem.2013.07.034","article-title":"Determination of bis phenol a migrating from canned food and beverages in markets","volume":"142","author":"Sungur","year":"2014","journal-title":"Food Chem."},{"issue":"10","key":"10.1016\/j.talanta.2025.129132_bib56","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1016\/j.fct.2012.07.059","article-title":"A review of dietary and non-dietary exposure to bisphenol-A","volume":"50","author":"Geens","year":"2012","journal-title":"Food Chem. Toxicol."},{"issue":"9","key":"10.1016\/j.talanta.2025.129132_bib57","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1289\/ehp.1306734","article-title":"Perinatally administered bisphenol a as a potential mammary gland carcinogen in rats","volume":"121","author":"Acevedo","year":"2013","journal-title":"Environ. Health Perspect."},{"issue":"4","key":"10.1016\/j.talanta.2025.129132_bib58","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1017\/S1368980015002116","article-title":"Estimating bisphenol A exposure levels using a questionnaire targeting known sources of exposure","volume":"19","author":"Nomura","year":"2016","journal-title":"Public Health Nutr."},{"issue":"3","key":"10.1016\/j.talanta.2025.129132_bib59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0090332","article-title":"Exposure to bisphenol A correlates with early-onset prostate cancer and promotes centrosome amplification and anchorage-independent growth in vitro","volume":"9","author":"Tarapore","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.talanta.2025.129132_bib60","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1210\/en.2013-1955","article-title":"Bisphenol A promotes human prostate stem-progenitor cell self-renewal and increases in vivo carcinogenesis in human prostate epithelium","volume":"155","author":"Prins","year":"2014","journal-title":"Endocrinol ogy"},{"issue":"2","key":"10.1016\/j.talanta.2025.129132_bib61","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1530\/ERC-16-0175","article-title":"Bisphenol A and its analogues disrupt centrosome cycle and microtu bule dynamics in prostate cancer","volume":"24","author":"Ho","year":"2017","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.talanta.2025.129132_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.envint.2017.06.012","article-title":"Bisphenol A and other environmental risk factors for prostate cancer in Hong Kong","volume":"107","author":"Tse","year":"2017","journal-title":"Environ. Int."},{"key":"10.1016\/j.talanta.2025.129132_bib63","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0300-483X(02)00260-3","article-title":"Diet and prostate cancer","volume":"181\u2013182","author":"Shirai","year":"2002","journal-title":"Toxicology"},{"issue":"23","key":"10.1016\/j.talanta.2025.129132_bib64","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1093\/jnci\/91.23.2038","article-title":"Heterocyclic amine content of cooked meat and risk of prostate cancer","volume":"91","author":"Norrish","year":"1999","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"10.1016\/j.talanta.2025.129132_bib65","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/pros.22643","article-title":"Consumption of deep-fried foods and risk of prostate cancer","volume":"73","author":"Stott-Miller","year":"2013","journal-title":"Prostate"},{"key":"10.1016\/j.talanta.2025.129132_bib66","series-title":"Cancer Epidemiology and Prevention","first-page":"1128","article-title":"Prostate cancer","author":"Platz","year":"2006"},{"issue":"6","key":"10.1016\/j.talanta.2025.129132_bib67","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1016\/j.juro.2008.08.042","article-title":"Vasectomy and the risk of prostate cancer","volume":"180","author":"Holt","year":"2008","journal-title":"J. Urol."},{"issue":"23","key":"10.1016\/j.talanta.2025.129132_bib68","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1001\/jama.287.23.3110","article-title":"Vasecto my and risk of prostate cancer","volume":"287","author":"Cox","year":"2002","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.talanta.2025.129132_bib69","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.contraception.2008.11.015","article-title":"On behalf of the HRP multicenter study of prostate cancer and Va sectomy. Prostate cancer and vasectomy: a hospital-based case-control study in China, Nepal and the Republic of Korea","volume":"79","author":"Schwingl","year":"2009","journal-title":"Contraception"},{"key":"10.1016\/j.talanta.2025.129132_bib70","first-page":"187","article-title":"Cancer mortality in an Italian rubber factory","volume":"44","author":"Bernardinelli","year":"1987","journal-title":"Br. J. Ind. Med."},{"key":"10.1016\/j.talanta.2025.129132_bib71","first-page":"1","article-title":"Mortality in the British rubber industry 1946\u20131985","volume":"46","author":"Sorahan","year":"1989","journal-title":"Br. J. Ind. Med."},{"key":"10.1016\/j.talanta.2025.129132_bib72","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/oem.57.3.180","article-title":"Exposure to high concen trations of nitrosamines and cancer mortality among a cohort of rubber workers","volume":"57","author":"Straif","year":"2000","journal-title":"Occup. Environ. Med."},{"key":"10.1016\/j.talanta.2025.129132_bib73","first-page":"115","article-title":"Cancer mortality in rubber tire workers in Poland","volume":"14","author":"Wilczynska","year":"2001","journal-title":"Int. J. Occup. Med. Environ. Health"},{"key":"10.1016\/j.talanta.2025.129132_bib74","first-page":"1","article-title":"An updated study of mor tality among North American synthetic rubber industry workers","volume":"132","author":"Delzell","year":"2006","journal-title":"Res. Rep. Health Eff. Inst."},{"key":"10.1016\/j.talanta.2025.129132_bib75","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1097\/00043764-199912000-00012","article-title":"A meta-analysis of risk estimates for prostate cancer related to tire and rubber manufacturing operations","volume":"41","author":"Stewart","year":"1999","journal-title":"J. Occup. Environ. Med."},{"key":"10.1016\/j.talanta.2025.129132_bib76","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1047-2797(97)00120-8","article-title":"Cancer among farmers: a meta-analysis","volume":"8","author":"Acquavella","year":"1998","journal-title":"Ann. Epidemiol."},{"key":"10.1016\/j.talanta.2025.129132_bib77","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/ajim.4700230507","article-title":"Cancer and other causes of death among male and female farmers from 23 states","volume":"23","author":"Blair","year":"1993","journal-title":"Am. J. Ind. Med."},{"key":"10.1016\/j.talanta.2025.129132_bib78","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/00043764-199904000-00010","article-title":"Cancer incidence in a cohort of licensed pesticide applicators in Florida","volume":"41","author":"Fleming","year":"1999","journal-title":"J. Occup. Environ. Med."},{"key":"10.1016\/j.talanta.2025.129132_bib79","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1136\/oem.60.9.634","article-title":"Occupation related pesticide expo sure and cancer of the prostate: a meta-analysis","volume":"60","author":"Van Maele-Fabry","year":"2003","journal-title":"Occup. Environ. Med."},{"key":"10.1016\/j.talanta.2025.129132_bib80","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s00420-004-0548-8","article-title":"Prostate cancer among pesticide applicators: a meta-analysis","volume":"77","author":"Van Maele-Fabry","year":"2004","journal-title":"Int. Arch. Occup. Environ. Health"},{"key":"10.1016\/j.talanta.2025.129132_bib81","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/CEJ.0b013e3280145b4c","article-title":"Pesticides and prostate cancer: a review of epidemiologic studies with specific agricultural exposure information","volume":"17","author":"Mink","year":"2008","journal-title":"Eur. J. Cancer Prev."},{"key":"10.1016\/j.talanta.2025.129132_bib82","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1097\/JOM.0b013e3181f72b7c","article-title":"An update of cancer incidence in the agricultural health study","volume":"52","author":"Koutros","year":"2010","journal-title":"J. Occup. Environ. Med."},{"key":"10.1016\/j.talanta.2025.129132_bib83","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1289\/ehp.9301","article-title":"Fonofos exposure and cancer incidence in the agricultural health study","volume":"114","author":"Mahajan","year":"2006","journal-title":"Environ. Health Perspect."},{"key":"10.1016\/j.talanta.2025.129132_bib84","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1289\/ehp.8911","article-title":"Phorate exposure and incidence of cancer in the agricultural health study","volume":"114","author":"Mahajan","year":"2006","journal-title":"Environ. Health Perspect."},{"key":"10.1016\/j.talanta.2025.129132_bib85","first-page":"871","article-title":"Occupational exposure to terbufos and the incidence of cancer in the agricultural health study","volume":"21","author":"Bonner","year":"2010","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.talanta.2025.129132_bib86","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1289\/ehp.0800446","article-title":"Coumaphos exposure and incident cancer among Male participants in the agricultural health study (AHS)","volume":"118","author":"Christensen","year":"2010","journal-title":"Environ. Health Perspect."},{"key":"10.1016\/j.talanta.2025.129132_bib87","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.envres.2009.06.006","article-title":"Cancer incidence among pesticide applicators exposed to butylate in the Agricultural Health Study (AHS)","volume":"109","author":"Lynch","year":"2009","journal-title":"Environ. Res."},{"key":"10.1016\/j.talanta.2025.129132_bib88","doi-asserted-by":"crossref","first-page":"9224","DOI":"10.1158\/0008-5472.CAN-10-1078","article-title":"Pesticide use mod ifies the association between genetic variants on chromosome 8q24 and prostate cancer","volume":"70","author":"Koutros","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.talanta.2025.129132_bib89","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/jnci\/87.9.652","article-title":"Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada","volume":"87","author":"Whittemore","year":"1995","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.talanta.2025.129132_bib90","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1093\/jnci\/85.19.1571","article-title":"a prospective study of dietary fat and risk of prostate cancer","volume":"85","author":"Giovannucci","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.talanta.2025.129132_bib91","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/(SICI)1097-0215(19971127)73:5<634::AID-IJC4>3.0.CO;2-Y","article-title":"Dietary fat intake and risk of prostate cancer: a prospective study of 25,708 Norwegian men","volume":"73","author":"Veierod","year":"1997","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.talanta.2025.129132_bib92","series-title":"GronbergH:Prostatecancerepidemiology.Lancet361","first-page":"859","year":"2003"},{"key":"10.1016\/j.talanta.2025.129132_bib93","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0300-483X(02)00260-3","article-title":"Diet and prostate cancer","volume":"181\u2013182","author":"Shirai","year":"2002","journal-title":"Toxicology"},{"key":"10.1016\/j.talanta.2025.129132_bib94","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1126\/science.279.5350.563","article-title":"Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study","volume":"279","author":"Chan","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.talanta.2025.129132_bib95","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1093\/jnci\/92.23.1910","article-title":"Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study","volume":"92","author":"Stattin","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.talanta.2025.129132_bib96","doi-asserted-by":"crossref","first-page":"4258","DOI":"10.1210\/jcem.85.11.6990","article-title":"Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer","volume":"85","author":"Harman","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.talanta.2025.129132_bib97","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/MOU.0b013e3280eb10fc","article-title":"Dietary intervention in the management of prostate cancer","volume":"17","author":"Demark-Wahne fried","year":"2007","journal-title":"Curr. Opin. Urol."},{"issue":"12 Suppl","key":"10.1016\/j.talanta.2025.129132_bib98","doi-asserted-by":"crossref","first-page":"3507S","DOI":"10.1093\/jn\/134.12.3507S","article-title":"Clinical trials in cancer prevention: current results and perspectives for the future","volume":"134","author":"Greenwald","year":"2004","journal-title":"J. Nutr."},{"issue":"7","key":"10.1016\/j.talanta.2025.129132_bib99","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1002\/ijc.22788","article-title":"Risk factors for prostate cancer incidence and progression in the health professionals follow-up study","volume":"121","author":"Giovannucci","year":"2007","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.talanta.2025.129132_bib100","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.urology.2004.08.035","article-title":"Obesity and prostate cancer","volume":"65","author":"Freedland","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.talanta.2025.129132_bib101","series-title":"Obesity and Aggressive Prostate Cancer Bias and Biomarkers","author":"Mcbride","year":"2012"},{"issue":"3","key":"10.1016\/j.talanta.2025.129132_bib102","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/1940-6207.CAPR-10-0014","article-title":"Obesity, endogenous hormone metabolism, and prostate cancer risk: a conundrum of \"highs\" and \"lows\"","volume":"3","author":"Kaaks","year":"2010","journal-title":"Cancer Prev. Res."},{"key":"10.1016\/j.talanta.2025.129132_bib103","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/136584","article-title":"Mechanisms of chronic state of inflammation as mediators that link obese adipose tissue and metabolic syn drome","volume":"2013","author":"Fuentes","year":"2013","journal-title":"Mediators Inflamm"},{"issue":"1","key":"10.1016\/j.talanta.2025.129132_bib104","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jpainsymman.2011.03.006","article-title":"Body composition, physical fit ness, functional performance, quality of life, and fatigue benefits of exercise for prostate cancer patients: a systematic review","volume":"43","author":"Keogh","year":"2012","journal-title":"J Pain Symptom Manage"},{"issue":"7","key":"10.1016\/j.talanta.2025.129132_bib105","first-page":"506","article-title":"Prostate cancer and sexually transmitted diseases: a meta-analysis","volume":"37","author":"Taylor","year":"2005","journal-title":"Fam. Med."},{"issue":"Suppl 10","key":"10.1016\/j.talanta.2025.129132_bib106","doi-asserted-by":"crossref","first-page":"K1","DOI":"10.1016\/j.vaccine.2008.05.064","article-title":"Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia","volume":"26","author":"Bosch","year":"2008","journal-title":"Vaccine"},{"issue":"4 Suppl","key":"10.1016\/j.talanta.2025.129132_bib107","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.jadohealth.2010.01.016","article-title":"Beyond cervical cancer: burden of other HPV-related cancers among men and women","volume":"46","author":"Chaturvedi","year":"2010","journal-title":"J. Adolesc. Health"},{"issue":"8","key":"10.1016\/j.talanta.2025.129132_bib108","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.2217\/fon.10.95","article-title":"Sexually transmitted infections and risk of prostate cancer: review of historical and emerging hypotheses","volume":"6","author":"Sutcliffe","year":"2010","journal-title":"Future Oncol."},{"key":"10.1016\/j.talanta.2025.129132_bib109","first-page":"91","article-title":"Human papillomavirus infection of the prostate","volume":"23","author":"Cuzick","year":"1995","journal-title":"Cancer Surv."},{"issue":"4","key":"10.1016\/j.talanta.2025.129132_bib110","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/(SICI)1097-0215(19980209)75:4<564::AID-IJC12>3.0.CO;2-9","article-title":"Sero-epidemiological associa tion between human-papillomavirus infection and risk of prostate cancer","volume":"75","author":"Dillner","year":"1998","journal-title":"Int. J. Cancer"},{"issue":"2","key":"10.1016\/j.talanta.2025.129132_bib111","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.mehy.2008.03.036","article-title":"Involvement of human papillomavirus infections in prostate cancer progression","volume":"71","author":"Al Moustafa","year":"2008","journal-title":"Med. Hypotheses"},{"issue":"6","key":"10.1016\/j.talanta.2025.129132_bib112","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1002\/(SICI)1097-0142(19980315)82:6<1118::AID-CNCR16>3.0.CO;2-9","article-title":"A multifaceted study of hu man papillomavirus and prostate carcinoma","volume":"82","author":"Strickler","year":"1998","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.talanta.2025.129132_bib113","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s11845-011-0692-6","article-title":"Human papillomavirus 16 or 18 infection and prostate can cer risk: a meta-analysis","volume":"180","author":"Lin","year":"2011","journal-title":"Ir. J. Med. Sci."},{"issue":"8","key":"10.1016\/j.talanta.2025.129132_bib114","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.2217\/fon.10.95","article-title":"Sexually transmitted infections and risk of prostate cancer: review of historical and emerging hypotheses","volume":"6","author":"Sutcliffe","year":"2010","journal-title":"Future Oncol."},{"issue":"10","key":"10.1016\/j.talanta.2025.129132_bib115","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1002\/ijc.31885","article-title":"Association between Trichomonas vaginalis and prostate cancer mor tality","volume":"144","author":"Tsang","year":"2019","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.talanta.2025.129132_bib116","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/oxfordjournals.epirev.a000795","article-title":"Hormones and prostate cancer: what\u2019s next?","volume":"23","author":"Hsing","year":"2001","journal-title":"Epidemiol. Rev."},{"key":"10.1016\/j.talanta.2025.129132_bib117","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/ijc.10810","article-title":"Early growth, adult body size and prostate cancer risk","volume":"103","author":"Giles","year":"2003","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.talanta.2025.129132_bib118","series-title":"Bone Mass and the Risk of Prostate Cancer: the Framingham Study","first-page":"734","author":"Zhang","year":"2002"},{"key":"10.1016\/j.talanta.2025.129132_bib119","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/ajcn\/74.4.549","article-title":"Dairy products, calcium, and prostate cancer risk in the Physicians' Health Study","volume":"74","author":"Chan","year":"2001","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.talanta.2025.129132_bib120","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1016\/S0022-5347(05)64461-8","article-title":"Vasectomy and prostate cancer characteristics of patients referred for prostate biopsy","volume":"168","author":"Chacko","year":"2002","journal-title":"J. Urol."},{"key":"10.1016\/j.talanta.2025.129132_bib121","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/pros.10120","article-title":"Does amount or type of alcohol influence the risk of prostate cancer?","volume":"52","author":"Albertsen","year":"2002","journal-title":"Prostate"},{"key":"10.1016\/j.talanta.2025.129132_bib122","unstructured":"Kumar Vinay, Abbas K Abul, Aster C. Jon, \u201cRobbins and Cotran Pathologic Basis of Disease\u201d, IX Edition, Copyright \u00a9 2015 by Saunders, an imprint of Elsevier Inc, Elsevier Saunders, Philadelphia, Page No.982-987."},{"issue":"5","key":"10.1016\/j.talanta.2025.129132_bib123","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1016\/j.juro.2011.07.013","article-title":"Multiparametric 3T prostate magnetic resonance imaging to detect cancer: histopathological correlation using prosta tectomy specimens processed in customized magnetic resonance imaging based molds","volume":"186","author":"Turkbey","year":"2011","journal-title":"J. Urol."},{"key":"10.1016\/j.talanta.2025.129132_bib124","series-title":"TNM Classification of Malignant Tumours","year":"2002"},{"issue":"1","key":"10.1016\/j.talanta.2025.129132_bib125","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/aja.2008.19","article-title":"Prostate cancer: diagnosis and staging","volume":"11","author":"Borley","year":"2009","journal-title":"Asian J. Androl."},{"key":"10.1016\/j.talanta.2025.129132_bib126","first-page":"125","article-title":"Classification of prostatic carcinoma","volume":"50","author":"Gleason","year":"1966","journal-title":"Cancer Chemother. Rep."},{"key":"10.1016\/j.talanta.2025.129132_bib127","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0022-5347(17)63039-8","article-title":"The histology and prognosis of prostatic cancer","volume":"97","author":"Mellinger","year":"1967","journal-title":"J. Urol."},{"key":"10.1016\/j.talanta.2025.129132_bib128","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0022-5347(17)59889-4","article-title":"The veterans administration cooperative urological research group. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging","volume":"111","author":"Gleason","year":"1974","journal-title":"J. Urol."},{"key":"10.1016\/j.talanta.2025.129132_bib129","series-title":"Urologic Pathology: the Prostate","first-page":"171","article-title":"The veterans administration cooperative urological research group. Histologic grading and clinical staging of prostatic caricnoma","author":"Gleason","year":"1977"},{"key":"10.1016\/j.talanta.2025.129132_bib130","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0046-8177(92)90108-F","article-title":"Histologic grading of prostate cancer: a perspective","volume":"23","author":"Gleason","year":"1992","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.talanta.2025.129132_bib131","series-title":"Pathology of the Prostate","first-page":"83","article-title":"Histologic grading of prostatic carcinoma","author":"Gleason","year":"1990"},{"issue":"3","key":"10.1016\/j.talanta.2025.129132_bib132","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/modpathol.3800054","article-title":"Gleason grading and prognostic factors in carcinoma of the prostate","volume":"17","author":"Humphrey","year":"2004","journal-title":"Mod. Pathol.: an official journal of the United States and Canadian Academy of Pathology, Inc"},{"key":"10.1016\/j.talanta.2025.129132_bib133","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ejphar.2018.07.034","article-title":"Molecular targeted therapy: treating cancer with specificity","volume":"834","author":"Lee","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.talanta.2025.129132_bib134","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel ormitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"deBono","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.talanta.2025.129132_bib135","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1210\/er.2002-0032","article-title":"Androgen receptor inprostatecancer","volume":"25","author":"Heinlein","year":"2004","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.talanta.2025.129132_bib136","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.steroids.2003.10.005","article-title":"The androgen receptor: a potential target for therapy of prostate cancer","volume":"69","author":"Santos","year":"2004","journal-title":"Steroids"},{"key":"10.1016\/j.talanta.2025.129132_bib137","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/jcb.20811","article-title":"Androgen receptor action in hormone-dependent and recurrent prostate cancer","volume":"99","author":"Agoulnik","year":"2006","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.talanta.2025.129132_bib138","doi-asserted-by":"crossref","first-page":"6407","DOI":"10.1158\/0008-5472.CAN-07-5997","article-title":"Androgen levels increase by intra tumoral de novo steroid oogenesis during progression of castration-resistant prostate cancer","volume":"68","author":"Locke","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.talanta.2025.129132_bib139","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/CCO.0b013e3283449400","article-title":"Novel agents and new therapeutics in castration-resistant prostate cancer","volume":"23","author":"Wu","year":"2011","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.talanta.2025.129132_bib140","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.talanta.2025.129132_bib141","first-page":"S77","article-title":"Growth factor receptor tyrosine kinase inhibitors; clinical devel opment and potential for prostate cancer therapy","volume":"170","author":"Black ledge","year":"2003","journal-title":"J.Urol."},{"key":"10.1016\/j.talanta.2025.129132_bib142","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/modpathol.2010.45","article-title":"Molecular alterations of EGFR and PTEN in prostate cancer: association with high-grade and advanced-stage carcinomas","volume":"23","author":"de Muga","year":"2010","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.talanta.2025.129132_bib143","doi-asserted-by":"crossref","first-page":"6579","DOI":"10.1158\/1078-0432.CCR-07-1257","article-title":"Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer","volume":"13","author":"Schlomm","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.talanta.2025.129132_bib144","doi-asserted-by":"crossref","first-page":"4725","DOI":"10.1200\/JCO.2004.06.134","article-title":"Racial disparity of epidermal growth factor receptor expression in prostate cancer","volume":"22","author":"Shuch","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.talanta.2025.129132_bib145","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.juro.2010.04.077","article-title":"Her-2\/neuexpression in prostate adenocarcinoma: a systematic review and meta-analysis","volume":"184","author":"Neto","year":"2010","journal-title":"J. Urol."},{"key":"10.1016\/j.talanta.2025.129132_bib146","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1158\/0008-5472.CAN-04-4292","article-title":"Inhibition of HER-2\/neukinase impairs androgen receptor recruitment to the androgen responsive enhancer","volume":"65","author":"Liu","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.talanta.2025.129132_bib147","first-page":"1253","article-title":"Inhibition of angiogenesis by the anti epidermal growth factor receptor antibody ImCloneC225 in androgen independentprostatecancergrowingorthotopicallyinnudemice","volume":"8","author":"Karashima","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.talanta.2025.129132_bib148","first-page":"1905","article-title":"Effects of anti-EGFR antibody cetuximabon androgen-independent prostate cancer cells,anticancer","volume":"30","author":"Dhupkar","year":"2010","journal-title":"Res."},{"key":"10.1016\/j.talanta.2025.129132_bib149","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1172\/JCI32278","article-title":"ErbB receptors: from oncogenes to targeted cancer therapies","volume":"117","author":"Zhang","year":"2007","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.talanta.2025.129132_bib150","doi-asserted-by":"crossref","first-page":"E77","DOI":"10.3816\/CGC.2009.n.028","article-title":"Anti-epidermal growth factor receptor monoclonal antibody cetuximab plus Doxorubicin in the treatment of metastatic castration-resistant prostate cancer","author":"Slovin","year":"2009","journal-title":"Clin.Genitourin.Cancer7"},{"key":"10.1016\/j.talanta.2025.129132_bib151","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0093-7754(01)90159-9","article-title":"Docetaxel, estramustine, plus trastuzumab in patients with metastatic androgen-independent prostate cancer","volume":"28","author":"Small","year":"2001","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.talanta.2025.129132_bib152","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ijrobp.2009.07.1731","article-title":"A phase I\/II trial of gefitinib given concurrently with radiotherapy in patients with non metastatic prostate cancer","volume":"78","author":"Joensuu","year":"2010","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.talanta.2025.129132_bib153","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.urology.2009.05.016","article-title":"Erlotinib has moderate single-agent activity in chemotherapy-naive castration- resistant prostate cancer: final results of a phase II trial","author":"Nabhan","year":"2009","journal-title":"Urology74"},{"key":"10.1016\/j.talanta.2025.129132_bib154","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1093\/annonc\/mdn174","article-title":"Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer","volume":"19","author":"Gravis","year":"2008","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.talanta.2025.129132_bib155","article-title":"A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer","author":"Whang","year":"2011","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.talanta.2025.129132_bib156","article-title":"A phase II study of cixutumumab(IMC-A12), a monoclonal antibody (MAb) against the insulin-like growth factor 1 receptor (IGF-IR), monotherapy in metastatic castration-resistant prostate cancer (mCRPC), 2010","author":"Higano","year":"2010","journal-title":"Genitourinary Cancers Symposium"},{"key":"10.1016\/j.talanta.2025.129132_bib157","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/978-3-540-31209-3_5","article-title":"Inhibition of the IGF-I receptor for treatment of cancer. Kinase inhibitors and monoclonal antibodies as alternative approaches","volume":"172","author":"Wang","year":"2007","journal-title":"Recent Results Cancer Res."},{"key":"10.1016\/j.talanta.2025.129132_bib158","first-page":"800","article-title":"A multi-institutional phase ii study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone refractory prostate cancer","volume":"7","author":"Ko","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.talanta.2025.129132_bib159","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s00280-011-1567-2","article-title":"Accelerated disease progression in prostate cancer and bone metastases with platelet-derived growth factor receptor inhibition: observations with tandutinib","volume":"68","author":"Mathew","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.talanta.2025.129132_bib160","doi-asserted-by":"crossref","first-page":"5549s","DOI":"10.1158\/1078-0432.CCR-07-1109","article-title":"IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor Ireceptor","volume":"13","author":"Rowin sky","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.talanta.2025.129132_bib161","article-title":"A phase II study of cixutumumab(IMC-A12), a monoclonal antibody (MAb) against the insulin-like growth factor 1 receptor (IGF-IR), monotherapy in metastatic castration-resistant prostate cancer (mCRPC),2010","author":"Higano","year":"2010","journal-title":"Genitourinary Cancers Symposium"},{"key":"10.1016\/j.talanta.2025.129132_bib162","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10549-005-6939-z","article-title":"Nor dihydro guaiaretic acid (NDGA)inhibits the IGF-1andc-erbB2\/HER2\/neureceptors and suppresses growth in breast cancer cells","volume":"94","author":"Youngren","year":"2005","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.talanta.2025.129132_bib163","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.cytogfr.2004.03.007","article-title":"The PDGF family: four gene products form five dimericiso forms","volume":"15","author":"Fredriksson","year":"2004","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.talanta.2025.129132_bib164","first-page":"549","article-title":"Immunohistochemistry analysis of platelet-derivedgrowthfactorAandBchainsandplatelet-derivedgrowth factoralphaandbetareceptorexpressioninbenignprostatichyperplasias and Gleason-graded human prostate adenocarcinomas","volume":"7","author":"Fudge","year":"1994","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.talanta.2025.129132_bib165","first-page":"1167","article-title":"Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4 (trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamide","volume":"3","author":"Shawver","year":"1997","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.talanta.2025.129132_bib166","first-page":"889","article-title":"Accelerated disease progression in prostate cancer and bone metastases with platelet-derived growth factor receptor inhibition: observations with tandutinib, Cancer Chem other","volume":"68","author":"Mathew","year":"2011","journal-title":"Pharmacol."},{"key":"10.1016\/j.talanta.2025.129132_bib167","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1756-8722-3-26","article-title":"Angiogenesisinhibitorsinthetreatmentofprostatecancer","volume":"3","author":"Hwang","year":"2010","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.talanta.2025.129132_bib168","first-page":"1932","article-title":"Prognosticsignificanceofplasmavascularendothelialgrowth factor levels inpatientswithhormone-refractoryprostatecancer treated on cancer and Leukemia Group B 9480","volume":"7","author":"George","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.talanta.2025.129132_bib169","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1309\/X6NXYE57DLUE2NQ8","article-title":"Endoglin(CD105)andvascularendothelialgrowthfactorasprognosticmarkers inprostaticadenocarcinoma","volume":"127","author":"El-Gohary","year":"2007","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.talanta.2025.129132_bib170","first-page":"3192","article-title":"Five differentanti-prostate-specificmembraneantigen(PSMA)antibodiesconfirm PSMAexpression intumor-associatedneovasculature","volume":"59","author":"Chang","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.talanta.2025.129132_bib171","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1158\/1078-0432.CCR-07-1355","article-title":"AphaseIIclinicaltrialofsorafenibinandrogen-independentprostatecan cer","volume":"14","author":"Dahut","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.talanta.2025.129132_bib172","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1093\/annonc\/mdm554","article-title":"AphaseIIstudyofsorafe nib inpatientswith chemo-naive castration-resistant prostate cancer","volume":"19","author":"Chi","year":"2008","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.talanta.2025.129132_bib173","series-title":"Randomized, placebo-controlled, phaseIIItrialofsunitinibincombinationwithprednisone(SU+P)versuspred nisone(P)aloneinmenwithprogressivemetastaticcastration-resistantpros tatecancer(mCRPC)","author":"Ou","year":"2011"},{"key":"10.1016\/j.talanta.2025.129132_bib174","series-title":"Neutralizing Anti-vascularendothelialgrowthfactorantibodycompletelyinhibitsangiogen Esisandgrowthofhumanprostatecarcinomamicrotumorsinvivo","first-page":"1","author":"Borgstrom","year":"1998"},{"key":"10.1016\/j.talanta.2025.129132_bib175","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY43-9006exhibitsbroadspectrumoral antitumoractivityandtargetstheRAF\/MEK\/ERKpathwayandreceptortyrosine kinases involvedintumorprogressionandangiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.talanta.2025.129132_bib176","first-page":"15","article-title":"Sorafenibinducesapoptosisandautophagy inprostatecancercellsinvitro","volume":"37","author":"Ullen","year":"2010","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.talanta.2025.129132_bib177","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/00042307-200109000-00006","article-title":"Mechanisms governing bone metastasis in prostate cancer","volume":"11","author":"Cher","year":"2001","journal-title":"Curr. Opin. Urol."},{"key":"10.1016\/j.talanta.2025.129132_bib178","first-page":"103","article-title":"Bone metastasis in prostate cancer: molecular and cellular mechanisms","volume":"20","author":"Ye","year":"2007","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.talanta.2025.129132_bib179","first-page":"345","article-title":"Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: maintaining the balance to prevent bone loss","volume":"5","author":"Trouvin","year":"2010","journal-title":"Clin. Interv. Aging"},{"key":"10.1016\/j.talanta.2025.129132_bib180","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1586\/14737140.7.2.221","article-title":"Key roles of the OPG\u2013RANK\u2013RANKL system in bone oncology","volume":"7","author":"Baud\u2019huin","year":"2007","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.talanta.2025.129132_bib181","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1158\/1541-7786.MCR-07-0117","article-title":"CXCL12\/CXCR4 transactivates HER2 in lipid rafts of prostate cancer cells and promotes growth of metastatic deposits in bone","volume":"6","author":"Chinni","year":"2008","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.talanta.2025.129132_bib182","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.urolonc.2007.05.008","article-title":"Proteases, growth factors, chemokines, and the microenvironment in prostate cancer bone metastasis","volume":"25","author":"Bonfil","year":"2007","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.talanta.2025.129132_bib183","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1359\/jbmr.2003.18.2.222","article-title":"Cathepsin K mRNA and protein expression in prostate cancer progression","volume":"18","author":"Brubaker","year":"2003","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.talanta.2025.129132_bib184","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nrm2821","article-title":"Regulation of cell signalling by uPAR","volume":"11","author":"Smith","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.talanta.2025.129132_bib185","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1517\/13543781003789388","article-title":"Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer","volume":"19","author":"Edwards","year":"2010","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.talanta.2025.129132_bib186","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1743-7563.2009.01266.x","article-title":"Evaluation of the safety, pharmacokinetics and treatment effects of an alpha(nu)beta(3) integrin inhibitor on bone turnover and disease activity in menwith hormone-refractory prostate cancer and bone metastases","volume":"6","author":"Rosenthal","year":"2010","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"10.1016\/j.talanta.2025.129132_bib187","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.talanta.2025.129132_bib188","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.talanta.2025.129132_bib189","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","article-title":"Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial","volume":"379","author":"Smith","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.talanta.2025.129132_bib190","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/pros.20744","article-title":"RANKL inhibition is an effective adjuvant for docetaxel in a prostate cancer bone metastases model","volume":"68","author":"Ignatoski","year":"2008","journal-title":"Prostate"},{"key":"10.1016\/j.talanta.2025.129132_bib191","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.bone.2008.09.009","article-title":"Influence of simultaneous targeting of the bone morphogenetic protein pathway and RANK\/RANKL axis in osteolytic prostate cancer lesion in bone","volume":"44","author":"Virk","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.talanta.2025.129132_bib192","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.bone.2010.11.003","article-title":"Combined inhibition of the BMP pathway and the RANK\u2013RANKL axis in a mixed lytic\/blastic prostate cancer lesion","volume":"48","author":"Virk","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.talanta.2025.129132_bib193","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/pros.20678","article-title":"RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes","volume":"68","author":"Armstrong","year":"2008","journal-title":"Prostate"},{"key":"10.1016\/j.talanta.2025.129132_bib194","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1158\/1535-7163.MCT-08-0046","article-title":"RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis","volume":"7","author":"Miller","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.talanta.2025.129132_bib195","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.urology.2011.01.006","article-title":"Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer","volume":"77","author":"Yu","year":"2011","journal-title":"Urology"},{"key":"10.1016\/j.talanta.2025.129132_bib196","doi-asserted-by":"crossref","first-page":"7421","DOI":"10.1158\/1078-0432.CCR-09-1691","article-title":"Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer","volume":"15","author":"Yu","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.talanta.2025.129132_bib197","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/cncr.26204","article-title":"Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1\u20132 study","volume":"118","author":"Araujo","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.talanta.2025.129132_bib198","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s00280-013-2079-z","article-title":"A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer","volume":"71","author":"Antonarakis","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.talanta.2025.129132_bib199","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1593\/neo.11122","article-title":"Targeting of alpha(v)-integrins in stem\/progenitor cells and supportive microenvironment impairs bone metastasis in human prostate cancer","volume":"13","author":"van der Horst","year":"2011","journal-title":"Neoplasia"},{"key":"10.1016\/j.talanta.2025.129132_bib200","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1002\/cncr.22996","article-title":"A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer","volume":"110","author":"Carducci","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.talanta.2025.129132_bib201","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1002\/cncr.23864","article-title":"Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer","volume":"113","author":"Nelson","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.talanta.2025.129132_bib202","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.eururo.2008.11.002","article-title":"Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial","volume":"55","author":"James","year":"2009","journal-title":"Eur. Urol."},{"key":"10.1016\/j.talanta.2025.129132_bib203","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1111\/j.1464-410X.2010.09638.x","volume":"106","author":"James","year":"2010","journal-title":"BJU Int."},{"key":"10.1016\/j.talanta.2025.129132_bib204","doi-asserted-by":"crossref","first-page":"5709","DOI":"10.1002\/cncr.27674","article-title":"Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate","volume":"118","author":"Nelson","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.talanta.2025.129132_bib205","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1200\/JCO.2012.46.4149","article-title":"Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer","volume":"31","author":"Fizazi","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.talanta.2025.129132_bib206","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.3390\/cancers12071752","article-title":"Immunotherapy in prostate cancer","volume":"12","author":"Fay","year":"2020","journal-title":"Cancers"},{"issue":"5256","key":"10.1016\/j.talanta.2025.129132_bib207","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity byCTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.talanta.2025.129132_bib208","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/s41591-020-0856-x","article-title":"Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune checkpoint inhibitors","volume":"26","author":"Schalper","year":"2020","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.talanta.2025.129132_bib209","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/annonc\/mdt107","article-title":"Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open label, multicenter phase I\/II study","volume":"24","author":"SlovinSF","year":"2013","journal-title":"Ann. Oncol."},{"issue":"7","key":"10.1016\/j.talanta.2025.129132_bib210","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","article-title":"Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial","volume":"15","author":"Kwon","year":"2014","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.talanta.2025.129132_bib211","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1200\/JCO.2016.69.1584","article-title":"Randomized, double-blind, phase III trial of ipilimumab ver sus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer","volume":"35","author":"Beer","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.talanta.2025.129132_bib212","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2020.07.032","article-title":"Final analysis of the ipilimumab versus placebo following radiotherapy phase iii trial in postdocetaxel metastatic castration resistant prostate cancer identifies an excess of long-term survivors","author":"Fizazi","year":"2020","journal-title":"Eur. Urol."},{"issue":"5","key":"10.1016\/j.talanta.2025.129132_bib213","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nm.4308","article-title":"VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer","volume":"23","author":"Gao","year":"2017","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.talanta.2025.129132_bib214","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1080\/19420862.2018.1466767","article-title":"The \u201cless-is-more\u201d in ther apeutic antibodies: afucosylated anti-cancer antibodies with en hanced antibody-dependent cellular cytotoxicity","volume":"10","author":"Pereira","year":"2018","journal-title":"mAbs"},{"issue":"10","key":"10.1016\/j.talanta.2025.129132_bib215","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1172\/JCI121924","article-title":"Immunogenomic analyses associate immuno logical alterations with mismatch repair defects in prostate cancer","volume":"128","author":"Nava Rodrigues","year":"2018","journal-title":"J. Clin. Investig."},{"issue":"11","key":"10.1016\/j.talanta.2025.129132_bib216","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.7150\/ijbs.41105","article-title":"ZhaoQ.B7-H3,acheckpointmolecule,asatarget for cancer immunotherapy","volume":"16","author":"YangS","year":"2020","journal-title":"Int. J. Biol. Sci."},{"issue":"16","key":"10.1016\/j.talanta.2025.129132_bib217","doi-asserted-by":"crossref","first-page":"7893","DOI":"10.1158\/0008-5472.CAN-07-1068","article-title":"B7-H3ligand expressionbyprostate cancer: a novel markerof prognosis and potential target for therapy","volume":"67","author":"Roth","year":"2007","journal-title":"Cancer Res."},{"issue":"15_suppl","key":"10.1016\/j.talanta.2025.129132_bib218","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1200\/JCO.2020.38.15_suppl.3071","article-title":"Preliminary dose escalation results from a phase I\/II, first-in human study of MGC018 (anti-B7-H3 antibody-drug conjugate) in patients with advanced solid tumors","volume":"38","author":"Powderly","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.talanta.2025.129132_bib219","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11912-018-0712-z","article-title":"Immunotherapy in prostate cancer: teaching an old dog new tricks","volume":"20","author":"Comiskey","year":"2018","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.talanta.2025.129132_bib220","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1200\/JCO.2005.04.5252","article-title":"Placebo-controlled phase III trial of immuno- logic therapy with sipuleucel-T (APC8015) in patients with meta- static, asymptomatic hormone refractory","volume":"24","author":"Small","year":"2006","journal-title":"prostate cancer. J. Clin. Oncol."},{"key":"10.1016\/j.talanta.2025.129132_bib221","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1002\/cncr.24429","article-title":"Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer","volume":"115","author":"Higano","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.talanta.2025.129132_bib222","article-title":"Immune-checkpoint inhibitors and metastatic prostate cancer therapy: learning by making mistakes","volume":"88","author":"Clapis","year":"2020","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.talanta.2025.129132_bib223","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s40259-015-0140-7","article-title":"Sipuleucel-T (Provenge((R))) autopsy of an innovative paradigm change in cancer treatment: why a single-product biotech company failed to capitalize on its breakthrough invention","volume":"29","author":"Jaroslawski","year":"2015","journal-title":"BioDrugs"},{"key":"10.1016\/j.talanta.2025.129132_bib224","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.3390\/ijms18122627","article-title":"Immunotherapy for prostate cancer: where we are headed","volume":"18","author":"Schepisi","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.talanta.2025.129132_bib225","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1517\/13543780902997928","article-title":"Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer","volume":"18","author":"Madan","year":"2009","journal-title":"Expert Opin. Investig. Drugs."},{"key":"10.1016\/j.talanta.2025.129132_bib226","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1200\/JCO.2009.25.0597","article-title":"Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer","volume":"28","author":"Kanto","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.talanta.2025.129132_bib227","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1200\/JCO.2009.25.0597","article-title":"Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer","volume":"28","author":"Kanto","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.talanta.2025.129132_bib228","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1158\/1078-0432.CCR-06-0145","article-title":"Phase I\/II trial of an allogeneic cellular immuno-therapy in hormone-naive prostate cancer","volume":"12","author":"Simons","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.talanta.2025.129132_bib229","doi-asserted-by":"crossref","DOI":"10.1016\/j.pdpdt.2021.102306","article-title":"Induced photo cytotoxicity on prostate cancer cells with the photodynamic action of toluidine blue ortho","volume":"34","author":"Topaloglu","year":"2021","journal-title":"Photodiagnosis Photodyn. Ther."},{"issue":"2","key":"10.1016\/j.talanta.2025.129132_bib230","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3390\/pharmaceutics14020241","article-title":"EGFR-targeted photodynamic therapy","volume":"14","author":"Ulfo","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.talanta.2025.129132_bib231","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.niox.2022.08.002","article-title":"Bystander effect in photosensitized prostate cancer cells with a different grade of malignancy: the role of nitric oxide","volume":"128","author":"Gani","year":"2022","journal-title":"Nitric Oxide"},{"key":"10.1016\/j.talanta.2025.129132_bib232","doi-asserted-by":"crossref","DOI":"10.1016\/j.pdpdt.2022.103035","article-title":"Noncanonical anti-cancer, anti-metastatic, anti-angiogenic and immunomodulatory PDT potentials of water soluble phthalocyanine derivatives with imidazole groups and their intracellular mechanism of action","volume":"39","author":"Ayaz","year":"2022","journal-title":"Photodiagnosis Photodyn. Ther."},{"issue":"9","key":"10.1016\/j.talanta.2025.129132_bib233","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/nrm2952","article-title":"Mitochondria and cell death: outer membrane permeabilization and beyond","volume":"11","author":"Tait","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.talanta.2025.129132_bib234","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1039\/D1DT03080A","article-title":"Photodynamic therapy with mitochondria-targeted biscyclometallated Ir(III) complexes. Multi-action mechanism and strong influence of the cyclometallating ligand","volume":"51","author":"Zafon","year":"2021","journal-title":"Dalton Trans"},{"key":"10.1016\/j.talanta.2025.129132_bib235","series-title":"Photodynamic Therapy (PDT)","author":"Fitzgerald","year":"2017"},{"key":"10.1016\/j.talanta.2025.129132_bib236","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.3390\/pharmaceutics13091332","article-title":"Photodynamic therapy review: principles, photosensitizers, applications, and future directions","volume":"13","author":"Correia","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.talanta.2025.129132_bib237","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41419-022-04851-4","article-title":"Which cell death modality wins the contest for photodynamic therapy of cancer?","volume":"13","author":"Mishchenko","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.talanta.2025.129132_bib238","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/php.13190","article-title":"Photodynamic therapy for cancer: what's past is prologue","volume":"96","author":"Hamblin","year":"2020","journal-title":"Photochem. Photobiol."},{"key":"10.1016\/j.talanta.2025.129132_bib239","doi-asserted-by":"crossref","first-page":"5195","DOI":"10.3390\/molecules25215195","article-title":"Daylight photodynamic therapy: an update","volume":"25","author":"Lee","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.talanta.2025.129132_bib240","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3390\/pharmaceutics14010196","article-title":"Induction of immunogenic cell death by photodynamic therapy mediated by aluminum-phthalocyanine in nanoemulsion","volume":"14","author":"Rodrigues","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.talanta.2025.129132_bib241","series-title":"Development of a Novel Photosensitizer for Photodynamic Therapy of Cancer","author":"Rocha","year":"2016"},{"key":"10.1016\/j.talanta.2025.129132_bib242","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.biopha.2018.07.049","article-title":"Photodynamic therapy\u2014Mechanisms, photosensitizers and combinations","volume":"106","author":"Kwiatkowski","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.talanta.2025.129132_bib243","first-page":"413","article-title":"Treatment options for localized prostate cancer","volume":"84","author":"Mohan","year":"2011","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/j.talanta.2025.129132_bib244","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.3390\/cancers3022516","article-title":"Cell death pathways in photodynamic therapy of cancer","volume":"3","author":"Mroz","year":"2011","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.talanta.2025.129132_bib245","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.eururo.2023.11.018","article-title":"Prostate-specific membrane antigen-targeted therapies for prostate cancer: towards improving therapeutic outcomes","volume":"85","author":"Corpetti","year":"2024","journal-title":"Eur. Urol."},{"key":"10.1016\/j.talanta.2025.129132_bib246","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.2967\/jnumed.117.191023","article-title":"(177) Lu-PSMA radioligand therapy for prostate cancer","volume":"58","author":"Fendler","year":"2017","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.talanta.2025.129132_bib247","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1007\/s00259-023-06316-y","article-title":"Opportunities and potential challenges of using terbium-161 for targeted radionuclide therapy in clinics","volume":"50","author":"Muller","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.talanta.2025.129132_bib248","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1053\/j.semnuclmed.2020.02.004","article-title":"(225)Ac-PSMA-617 for therapy of prostate cancer","volume":"50","author":"Kratochwil","year":"2020","journal-title":"Semin. Nucl. Med."},{"key":"10.1016\/j.talanta.2025.129132_bib249","doi-asserted-by":"crossref","first-page":"5182","DOI":"10.1158\/1078-0432.CCR-13-0231","article-title":"Phase II study of lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer","volume":"19","author":"Tagawa","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.talanta.2025.129132_bib250","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.talanta.2025.129132_bib251","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.2967\/jnumed.115.158550","article-title":"68Ga- and 177Lu labeled PSMA I&T: optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies","volume":"56","author":"Weineisen","year":"2015","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.talanta.2025.129132_bib252","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.2967\/jnumed.123.265524","article-title":"Albumin-binding and conventional PSMA ligands in combination with (161)Tb: biodistribution, dosimetry, and preclinical therapy","volume":"64","author":"Tschan","year":"2023","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.talanta.2025.129132_bib253","doi-asserted-by":"crossref","first-page":"5651","DOI":"10.3390\/cancers14225651","article-title":"[(225)Ac]Ac-SibuDAB for targeted alpha therapy of prostate cancer: preclinical evaluation and comparison with [(225)Ac]Ac PSMA-617","volume":"14","author":"Busslinger","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.talanta.2025.129132_bib254","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s00259-020-05022-3","article-title":"Biodistribution and dosimetry of a single dose of albumin-binding ligand [(177)Lu]Lu PSMA-ALB-56 in patients with mCRPC","volume":"48","author":"Kramer","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.talanta.2025.129132_bib255","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.talanta.2025.129132_bib256","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.euf.2021.06.006","article-title":"Prostate-specific membrane antigen biology in lethal prostate cancer and its therapeutic implications","volume":"8","author":"Sheehan","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.talanta.2025.129132_bib257","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody-drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"530","key":"10.1016\/j.talanta.2025.129132_bib258","first-page":"e15","article-title":"Phase 1\/2 multiple ascending dose trial of the prostate-specific membrane antigen targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer","volume":"34","author":"Milowsky","year":"2016","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.talanta.2025.129132_bib259","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/pros.23922","article-title":"PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and\/or enzalutamide: efficacy and safety in open-label single-arm phase 2 study","volume":"80","author":"Petrylak","year":"2020","journal-title":"Prostate"},{"key":"10.1016\/j.talanta.2025.129132_bib260","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.1158\/1078-0432.CCR-20-4528","article-title":"Phase I study of MEDI3726: a prostate-specific membrane antigen-targeted antibody-drug conjugate, in patients with mCRPC after failure of abiraterone or enzalutamide","volume":"27","author":"de","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.talanta.2025.129132_bib261","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1158\/1535-7163.MCT-22-0160","article-title":"Modular smart molecules for PSMA-targeted chemotherapy","volume":"21","author":"Olatunji","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.talanta.2025.129132_bib262","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3390\/cancers13030417","article-title":"Small molecule-based prodrug targeting prostate specific membrane antigen for the treatment of prostate cancer","volume":"13","author":"Wang","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.talanta.2025.129132_bib263","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.talanta.2025.129132_bib264","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41585-021-00488-8","article-title":"The potential of CAR T cell therapy for prostate cancer","volume":"18","author":"Wolf","year":"2021","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.talanta.2025.129132_bib265","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis","volume":"19","author":"Quail","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.talanta.2025.129132_bib266","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102975","article-title":"CAR-NK cells: a promising cellular immunotherapy for cancer","volume":"59","author":"Xie","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.talanta.2025.129132_bib267","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","article-title":"T cell-engaging therapies\u2014BiTEs and beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.talanta.2025.129132_bib268","doi-asserted-by":"crossref","first-page":"549","DOI":"10.3390\/cancers13030549","article-title":"Bispecific antibodies in prostate cancer therapy: current status and perspectives","volume":"13","author":"Heitmann","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"6_suppl","key":"10.1016\/j.talanta.2025.129132_bib269","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1200\/JCO.2023.41.6_suppl.153","article-title":"Early dose escalation of LAVA-1207, a novel bispecific gamma-delta T-cell engager (Gammabody), in patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"41","author":"Mehra","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.talanta.2025.129132_bib270","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41577-020-00452-4","article-title":"Gammadelta T cells in tissue physiology and surveillance","volume":"21","author":"Ribot","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.talanta.2025.129132_bib271","article-title":"Novel serum proteomic biomarkers for early diagnosis and aggressive grade identification of prostate cancer","volume":"12","author":"Wang","year":"2022","journal-title":"Front. Oncol."},{"issue":"11","key":"10.1016\/j.talanta.2025.129132_bib272","doi-asserted-by":"crossref","first-page":"5688","DOI":"10.1111\/jcmm.13845","article-title":"Plasma ghrelin O-acyltransferase (GOAT) enzyme levels: a novel non-invasive diagnosis tool for patients with significant prostate cancer","volume":"22","author":"G\u00f3mez-G\u00f3mez","year":"2018","journal-title":"J. Cell Mol. Med."},{"issue":"6","key":"10.1016\/j.talanta.2025.129132_bib273","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1007\/s13277-015-3045-7","article-title":"Plasma proteasomal chymotrypsin-like activity correlates with prostate cancer pro gression","volume":"36","author":"Deng","year":"2015","journal-title":"Tumor Biol."},{"issue":"1","key":"10.1016\/j.talanta.2025.129132_bib274","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1038\/s41598-021-81965-3","article-title":"Integrating inflammatory serum biomarkers into a risk calculator for prostate cancer detec tion","volume":"11","author":"Jalali","year":"2021","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.talanta.2025.129132_bib275","doi-asserted-by":"crossref","first-page":"368","DOI":"10.5534\/wjmh.210072","article-title":"Genomic profiling of prostate cancer: an updated review","volume":"40","author":"Hatano","year":"2022","journal-title":"World J Mens Health"},{"key":"10.1016\/j.talanta.2025.129132_bib276","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.omto.2023.07.004","article-title":"Current advances of liquid biopsies in prostate cancer: molecular biomarkers","volume":"30","author":"Alahdal","year":"2023","journal-title":"Molecul Therapy- Oncolyt."},{"issue":"3","key":"10.1016\/j.talanta.2025.129132_bib277","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/mutage\/geaa010","article-title":"Genome-wide association study of germline copy number variations reveals an association with prostate cancer aggressiveness","volume":"35","author":"Brezina","year":"2020","journal-title":"Mutagenesis"},{"key":"10.1016\/j.talanta.2025.129132_bib278","series-title":"BEST (Biomarkers, Endpoints, and Other Tools) Resource.","year":"2016"},{"key":"10.1016\/j.talanta.2025.129132_bib279","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1172\/JCI100974","article-title":"An \u201cacid\u201d phosphatase occurring in the serum of patients with metasta sizing carcinoma of the prostate gland","volume":"17","author":"Guman","year":"1938","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.talanta.2025.129132_bib280","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1677\/erc.1.00950","article-title":"Cellular prostatic acid phosphatase: a protein tyrosine phosphatase involved in androgen-independent proliferation of prostate cancer","volume":"12","author":"Veeramani","year":"2005","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.talanta.2025.129132_bib281","first-page":"293","article-title":"Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate","volume":"1","author":"Huggins","year":"1941","journal-title":"Cancer Res."},{"key":"10.1016\/j.talanta.2025.129132_bib282","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S0022-5347(17)50207-4","article-title":"Acid phosphatase: its influence on the management of carcinoma of the prostate","volume":"131","author":"Whitesel","year":"1984","journal-title":"J. Urol."},{"key":"10.1016\/j.talanta.2025.129132_bib283","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0090-4295(76)90337-X","article-title":"Clinical significance of serum acid phosphatase levels in advanced prostatic carcinoma","volume":"8","author":"Johnson","year":"1976","journal-title":"Urology"},{"key":"10.1016\/j.talanta.2025.129132_bib284","first-page":"589","article-title":"Prostaticacidphosphatasein1993.Itslimitedclinical utility","volume":"20","author":"LoweFC","year":"1993","journal-title":"Urol. Clin. North Am."},{"key":"10.1016\/j.talanta.2025.129132_bib285","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S0090-4295(00)01073-6","article-title":"Serum acid phosphatase level and biochemical recurrence following radical prostatectomy for men with clinically localized prostate cancer","volume":"57","author":"HanM","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.talanta.2025.129132_bib286","first-page":"1003","article-title":"Revivingtheacidphosphatasetestforprostatecancer","volume":"21","author":"TairaA","year":"2007","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.talanta.2025.129132_bib287","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.biochi.2015.09.023","article-title":"Kallikreins \u2013 the melting pot of activity and function","volume":"122","author":"Kalinska","year":"2016","journal-title":"Biochimie"},{"key":"10.1016\/j.talanta.2025.129132_bib288","first-page":"22","article-title":"Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer","volume":"1776","author":"Pampalakis","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.talanta.2025.129132_bib289","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1056\/NEJMe048003","article-title":"Prostate cancers in men with low PSA levels \u2013 must we find them?","volume":"350","author":"Carter","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.talanta.2025.129132_bib290","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.cca.2014.06.019","article-title":"The influence of prostate volume in prostate health index perfor mance in patients with total PSA lower than 10\u03bcg\/L","volume":"436","author":"Filella","year":"2014","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.talanta.2025.129132_bib291","article-title":"Liquid biomarkers in prostate cancer diagnosis: current status and emerging prospects","volume":"42","author":"Liu","year":"2024","journal-title":"World J Mens Health"},{"issue":"4","key":"10.1016\/j.talanta.2025.129132_bib292","doi-asserted-by":"crossref","first-page":"438","DOI":"10.4103\/0975-2870.186079","article-title":"Moving ahead of prostate-specific antigen","volume":"9","author":"Iqbal","year":"2016","journal-title":"Med J DYPatil Univ"},{"issue":"5","key":"10.1016\/j.talanta.2025.129132_bib293","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.juro.2010.12.032","article-title":"A multicenter study of [-2]pro-prostate specific antigen combined with prostate spe cific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng\/ml prostate specific antigen range","volume":"185","author":"Catalona","year":"2011","journal-title":"J. Urol."},{"issue":"13","key":"10.1016\/j.talanta.2025.129132_bib294","article-title":"Value of free\/total prostate-specific antigen (f\/t PSA) ratios for prostate cancer detection in patients with total serum prostate-specific antigen between 4 and 10ng\/mL: a meta-analysis","volume":"97","author":"Huang","year":"2018","journal-title":"Medicine (Baltim.)"},{"issue":"8","key":"10.1016\/j.talanta.2025.129132_bib295","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.3390\/ijms20081813","article-title":"A rich array of prostate cancer molecular biomarkers: opportunities and challenges","volume":"20","author":"Kohaar","year":"2019","journal-title":"IJMS"},{"issue":"4","key":"10.1016\/j.talanta.2025.129132_bib296","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/j.juro.2009.12.056","article-title":"[-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study","volume":"183","author":"LeBV","year":"2010","journal-title":"J. Urol."},{"issue":"1","key":"10.1016\/j.talanta.2025.129132_bib297","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ajur.2014.08.007","article-title":"Prostate cancer in Asia: a collab orative report","volume":"1","author":"Chen","year":"2014","journal-title":"Asian J Urol"},{"issue":"5","key":"10.1016\/j.talanta.2025.129132_bib298","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1007\/s00345-019-02889-2","article-title":"Combining prostate health index and multiparametric magnetic resonance imaging in the diagno sis of clinically significant prostate cancer in an Asian popula tion","volume":"38","author":"Hsieh","year":"2020","journal-title":"World J. Urol."},{"issue":"12","key":"10.1016\/j.talanta.2025.129132_bib299","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1007\/s00345-023-04644-0","article-title":"Ethnic differences in prostate cancer presentation: a time for testing advocacy","volume":"41","author":"Batura","year":"2023","journal-title":"World J. Urol."},{"issue":"1","key":"10.1016\/j.talanta.2025.129132_bib300","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12894-016-0137-7","article-title":"Do African-American men need separate prostate cancer screening guidelines?","volume":"16","author":"Shenoy","year":"2016","journal-title":"BMC Urol."},{"issue":"3","key":"10.1016\/j.talanta.2025.129132_bib301","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1097\/JU.0000000000001453","article-title":"Performance of pros tate health index in biopsy na\u00efve black men","volume":"205","author":"Babajide","year":"2021","journal-title":"J. Urol."},{"issue":"21","key":"10.1016\/j.talanta.2025.129132_bib302","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.3390\/diagnostics13213350","article-title":"Biomarkers for prostate cancer: from diagnosis to treatment","volume":"13","author":"Chen","year":"2023","journal-title":"Diagnostics"},{"issue":"5","key":"10.1016\/j.talanta.2025.129132_bib303","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1016\/S0022-5347(05)64263-2","article-title":"Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen","volume":"168","author":"Steuber","year":"2002","journal-title":"J. Urol."},{"issue":"12","key":"10.1016\/j.talanta.2025.129132_bib304","first-page":"2312","article-title":"Singlenucleotidepoly morphism of the human kallikrein-2 gene highly correlates with serumhumankallikrein-2levelsandincombinationenhancespros tate cancer detection","volume":"21","author":"NamRK","year":"2003","journal-title":"J. Clin. Orthod."},{"key":"10.1016\/j.talanta.2025.129132_bib305","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1741-7015-6-19","article-title":"A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European randomized study of prostate cancer screening in G\u00f6teborg, Sweden","volume":"6","author":"Vickers","year":"2008","journal-title":"BMC Med."},{"issue":"1","key":"10.1016\/j.talanta.2025.129132_bib306","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1186\/1471-2407-12-507","article-title":"PCA3 noncoding RNA is involved in the control of prostate-cancer cell survival and modulates androgen receptor signaling","volume":"12","author":"Ferreira","year":"2012","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.talanta.2025.129132_bib307","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.tranon.2018.02.019","article-title":"Clinical significance of peripheral blood PCA3 gene expression in early diagnosis of prostate cancer","volume":"11","author":"Chunhua","year":"2018","journal-title":"Transl. Oncol."},{"issue":"27","key":"10.1016\/j.talanta.2025.129132_bib308","doi-asserted-by":"crossref","first-page":"8403","DOI":"10.1073\/pnas.1507882112","article-title":"PRUNE2 is a human prostatecancersuppressorregulatedbytheintroniclongnoncoding RNAPCA3","volume":"112","author":"Salameh","year":"2015","journal-title":"ProcNatlAcadSciU SA"},{"issue":"4","key":"10.1016\/j.talanta.2025.129132_bib309","doi-asserted-by":"crossref","first-page":"438","DOI":"10.4103\/0975-2870.186079","article-title":"Moving ahead of prostate-specific antigen","volume":"9","author":"Iqbal","year":"2016","journal-title":"Med J DYPatil Univ"},{"issue":"3","key":"10.1016\/j.talanta.2025.129132_bib310","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.urology.2006.12.014","article-title":"PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy","volume":"69","author":"Marks","year":"2007","journal-title":"Urology"},{"issue":"3","key":"10.1016\/j.talanta.2025.129132_bib311","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41391-022-00562-1","article-title":"Clinical use of the mRNA urinary biomarker SelectMDx test for prostate cancer","volume":"25","author":"Visser","year":"2022","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"11","key":"10.1016\/j.talanta.2025.129132_bib312","doi-asserted-by":"crossref","first-page":"18497","DOI":"10.18632\/oncotarget.14501","article-title":"Prostate cancer proteo mics: current trends and future perspectives for biomarker dis covery","volume":"8","author":"Tanase","year":"2017","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.talanta.2025.129132_bib313","doi-asserted-by":"crossref","first-page":"5688","DOI":"10.1111\/jcmm.13845","article-title":"Plasma ghrelin O-acyltransferase (GOAT) enzyme levels: a novel non-invasive diagnosis tool for patients with significant prostate cancer","volume":"22","author":"G\u00f3mez-G\u00f3mez","year":"2018","journal-title":"J. Cell Mol. Med."},{"issue":"6","key":"10.1016\/j.talanta.2025.129132_bib314","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1007\/s13277-015-3045-7","article-title":"Plasma proteasomal chymotrypsin-like activity correlates with prostate cancer pro gression","volume":"36","author":"Deng","year":"2015","journal-title":"Tumor Biol."},{"issue":"1","key":"10.1016\/j.talanta.2025.129132_bib315","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1038\/s41598-021-81965-3","article-title":"Integrating inflammatory serum biomarkers into a risk calculator for prostate cancer detec tion","volume":"11","author":"Jalali","year":"2021","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.talanta.2025.129132_bib316","doi-asserted-by":"crossref","first-page":"368","DOI":"10.5534\/wjmh.210072","article-title":"Genomic profiling of prostate cancer: an updated review","volume":"40","author":"Hatano","year":"2022","journal-title":"World J Mens Health"},{"key":"10.1016\/j.talanta.2025.129132_bib317","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.omto.2023.07.004","article-title":"Current advances of liquid biopsies in prostate cancer: molecular biomarkers","volume":"30","author":"Alahdal","year":"2023","journal-title":"Molecul Therapy- Oncolyt."},{"issue":"4","key":"10.1016\/j.talanta.2025.129132_bib318","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3390\/cancers11040459","article-title":"The human microbiota and prostate cancer: friend or foe?","volume":"11","author":"Massari","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.talanta.2025.129132_bib319","first-page":"122","article-title":"Theroleofgut microbiome in the pathogenesis of prostate cancer: a prospec tive","volume":"111","author":"GolombosDM","year":"2018","journal-title":"pilot study. Urology."},{"issue":"10","key":"10.1016\/j.talanta.2025.129132_bib320","doi-asserted-by":"crossref","first-page":"4950","DOI":"10.3390\/cimb44100336","article-title":"Effect of radium-223 on the gut microbiota of prostate cancer patients: a pilot case series study","volume":"44","author":"Fernandes","year":"2022","journal-title":"CIMB"},{"issue":"1","key":"10.1016\/j.talanta.2025.129132_bib321","first-page":"169","article-title":"A prospective, population-based study of andro stenedione, estrogens, and prostatic cancer","volume":"50","author":"Barrett-Connor","year":"1990","journal-title":"Cancer Res."},{"key":"10.1016\/j.talanta.2025.129132_bib322","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.maturitas.2017.06.025","article-title":"Estrogen\u2013gut microbiome axis: physiological and clinical implications","volume":"103","author":"Baker","year":"2017","journal-title":"Maturitas"},{"key":"10.1016\/j.talanta.2025.129132_bib323","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.eururo.2016.08.037","article-title":"DNA repair in prostate cancer: biology and clinical implications","volume":"71","author":"Mateo","year":"2017","journal-title":"Eur. Urol."},{"key":"10.1016\/j.talanta.2025.129132_bib324","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.talanta.2025.129132_bib325","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1535-6108(03)00248-4","article-title":"Targeting the PI3K-Akt pathway in human cancer: rationale and promise","volume":"4","author":"Luo","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.talanta.2025.129132_bib326","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.talanta.2025.129132_bib327","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ccr.2010.05.026","article-title":"Integrative genomic profiling of human prostate cancer","volume":"18","author":"Taylor","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.talanta.2025.129132_bib328","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.cell.2013.03.021","article-title":"Punctuated evolution of prostate cancer genomes","volume":"153","author":"Baca","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.talanta.2025.129132_bib329","article-title":"Randomized phase II study evaluating akt blockade with ipatasertib, in combination with abiraterone, in patients with metastatic prostate cancer with and without PTEN loss","volume":"25","author":"DBJ","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.talanta.2025.129132_bib330","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1158\/1078-0432.CCR-20-0394","article-title":"Non-BRCA DNA damage repair gene alterations and response to PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer: analysis from the phase II TRITON2 study","volume":"26","author":"Abida","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.talanta.2025.129132_bib331","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/nrurol.2017.144","article-title":"WNT signalling in prostate cancer","volume":"14","author":"Murillo-Garzon","year":"2017","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.talanta.2025.129132_bib332","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1080\/14656566.2017.1329820","article-title":"Darolutamide (ODM-201) for the treatment of prostate cancer","volume":"18","author":"Shore","year":"2017","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.talanta.2025.129132_bib333","doi-asserted-by":"crossref","DOI":"10.1038\/srep12007","article-title":"Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling directed prostate cancer therapies","volume":"5","author":"Moilanen","year":"2015","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.talanta.2025.129132_bib334","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/nrg.2018.4","article-title":"Integrative omics for health and disease","volume":"19","author":"Karczewski","year":"2018","journal-title":"Nat. Rev. Genet."},{"issue":"1","key":"10.1016\/j.talanta.2025.129132_bib335","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12711-016-0217-x","article-title":"Multi-omic data integra tion and analysis using systems genomics approaches: methods and applications in animal production, health and welfare","volume":"48","author":"Suravajhala","year":"2016","journal-title":"Genet. Sel. Evol."},{"issue":"37","key":"10.1016\/j.talanta.2025.129132_bib336","doi-asserted-by":"crossref","first-page":"4221","DOI":"10.2174\/0929867323666160926150617","article-title":"Overview of systems biology and omics technologies","volume":"23","author":"Karahalil","year":"2016","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.talanta.2025.129132_bib337","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/nrg.2018.4","article-title":"Integrative omics for health and disease","volume":"19","author":"Karczewski","year":"2018","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.talanta.2025.129132_bib338","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.cell.2017.08.007","article-title":"High-definition medicine","volume":"170","author":"Torkamani","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.talanta.2025.129132_bib339","doi-asserted-by":"crossref","DOI":"10.1002\/pmic.201700463","article-title":"Clinical proteomics: closing the gap from discovery to implementation","volume":"18","author":"Frantzi","year":"2018","journal-title":"Proteomics"},{"key":"10.1016\/j.talanta.2025.129132_bib340","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/01.cco.0000147382.97085.e4","article-title":"Apply innovative technologies to explore cancer genome","volume":"17","author":"Shih","year":"2005","journal-title":"Curr. Opin. Oncol."},{"issue":"5","key":"10.1016\/j.talanta.2025.129132_bib341","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/ng2022","article-title":"Genome wide association study of prostate cancer identifies a second risk locus at 8q24","volume":"39","author":"Yeager","year":"2007","journal-title":"Nat. Genet."},{"issue":"3","key":"10.1016\/j.talanta.2025.129132_bib342","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/ng.90","article-title":"Multiple newly identified loci associated with prostate cancer susceptibility","volume":"40","author":"Eeles","year":"2008","journal-title":"Nat. Genet."},{"issue":"10","key":"10.1016\/j.talanta.2025.129132_bib343","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/ng.450","article-title":"Identification of seven new prostate cancer susceptibility loci through a genome wide association study","volume":"41","author":"Eeles","year":"2009","journal-title":"Nat. Genet."},{"issue":"4","key":"10.1016\/j.talanta.2025.129132_bib344","doi-asserted-by":"crossref","DOI":"10.1038\/ng.2560","article-title":"Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array","volume":"45","author":"Eeles","year":"2013","journal-title":"Nat. Genet."},{"issue":"2","key":"10.1016\/j.talanta.2025.129132_bib345","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/ng.2862","article-title":"A prostate cancer susceptibility allele at 6q22 increases RFX6 expression by modulating HOXB13 chromatin binding","volume":"46","author":"Huang","year":"2014","journal-title":"Nat. Genet."},{"issue":"5","key":"10.1016\/j.talanta.2025.129132_bib346","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.talanta.2025.129132_bib347","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1158\/1055-9965.EPI-12-0495","article-title":"Confirmation of the HOXB13 G84E germline mutation in familial prostate cancer","volume":"21","author":"Breyer","year":"2012","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"issue":"9","key":"10.1016\/j.talanta.2025.129132_bib348","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1158\/2159-8290.CD-16-0960","article-title":"Exome sequencing of African-American prostate cancer reveals loss-of-function mutations","volume":"7","author":"Huang","year":"2017","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.talanta.2025.129132_bib349","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12894-016-0137-7","article-title":"Do African-American men need separate prostate cancer screening guidelines?","volume":"16","author":"Shenoy","year":"2016","journal-title":"BMC Urol."},{"issue":"1","key":"10.1016\/j.talanta.2025.129132_bib350","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ccr.2010.05.026","article-title":"Integrative genomic profiling of human prostate cancer","volume":"18","author":"Taylor","year":"2010","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.talanta.2025.129132_bib351","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/ng.2279","article-title":"Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer","volume":"44","author":"Barbieri","year":"2012","journal-title":"Nat. Genet."},{"issue":"7406","key":"10.1016\/j.talanta.2025.129132_bib352","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nature11125","article-title":"The mutational landscape of lethal castration-resistant prostate cancer","volume":"487","author":"Grasso","year":"2012","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.talanta.2025.129132_bib353","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ccr.2013.01.002","article-title":"Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer","volume":"23","author":"Weischenfeldt","year":"2013","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.talanta.2025.129132_bib354","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","article-title":"The molecular taxonomy of primary prostate cancer","volume":"163","year":"2015","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.talanta.2025.129132_bib355","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nm.4045","article-title":"Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer","volume":"22","author":"Beltran","year":"2016","journal-title":"Nat. Med."},{"issue":"7637","key":"10.1016\/j.talanta.2025.129132_bib356","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nature20788","article-title":"Genomic hallmarks of localized, non-indolent prostate cancer","volume":"541","author":"Fraser","year":"2017","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.talanta.2025.129132_bib357","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.cell.2015.06.053","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"162","author":"Robinson","year":"2015","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.talanta.2025.129132_bib358","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1158\/1078-0432.CCR-13-1982","article-title":"Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma","volume":"20","author":"Tan","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"5748","key":"10.1016\/j.talanta.2025.129132_bib359","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1126\/science.1117679","article-title":"Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer","volume":"310","author":"Tomlins","year":"2005","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.talanta.2025.129132_bib360","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.eururo.2009.04.036","article-title":"ETS gene fusions in prostate cancer: from discovery to daily clinical practice","volume":"56","author":"Tomlins","year":"2009","journal-title":"Eur. Urol."},{"key":"10.1016\/j.talanta.2025.129132_bib361","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3233\/CBM-2006-23-404","article-title":"Genomic approach to biomarker identification and its recent applications","volume":"2","author":"He","year":"2006","journal-title":"Cancer Biomark"},{"issue":"3","key":"10.1016\/j.talanta.2025.129132_bib362","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.molcel.2018.07.017","article-title":"Emerging principles of gene expression programs and their regulation","volume":"71","author":"Pope","year":"2018","journal-title":"Mol. Cell"},{"key":"10.1016\/j.talanta.2025.129132_bib363","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.cbpa.2019.05.031","article-title":"Visualizing transcription: key to understanding gene expression dynamics","volume":"51","author":"Brouwer","year":"2019","journal-title":"Curr. Opin. Chem. Biol."},{"issue":"3","key":"10.1016\/j.talanta.2025.129132_bib364","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics8030062","article-title":"Genome-based classi f ication and therapy of prostate cancer","volume":"8","author":"Angeles","year":"2018","journal-title":"Diagnostics"},{"issue":"9","key":"10.1016\/j.talanta.2025.129132_bib365","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1101\/gr.247239.118","article-title":"Decrypting noncoding RNA interac tions, structures, and functional networks","volume":"29","author":"Fabbri","year":"2019","journal-title":"Genome Res."},{"issue":"17","key":"10.1016\/j.talanta.2025.129132_bib366","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.7150\/thno.21299","article-title":"Identifying and characterizing circRNA-protein interaction","volume":"7","author":"Du","year":"2017","journal-title":"Theranostics"},{"issue":"10","key":"10.1016\/j.talanta.2025.129132_bib367","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/j.ymthe.2019.09.001","article-title":"ncRNA-Encoded peptides or proteins and cancer","volume":"27","author":"Wang","year":"2019","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.talanta.2025.129132_bib368","doi-asserted-by":"crossref","DOI":"10.1038\/nrc.2017.99","article-title":"Non-coding RNA networks in cancer","volume":"18","author":"Anastasiadou","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.talanta.2025.129132_bib369","first-page":"407","article-title":"MicroRNAs in prostate cancer: functional role as biomarkers","author":"Kanwal","year":"2017","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.talanta.2025.129132_bib370","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s13046-018-0813-4","article-title":"Downregulation of miR 133a-3p promotes prostate cancer bone metastasis via activating PI3K\/AKT sig naling","volume":"37","author":"Tang","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.talanta.2025.129132_bib371","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19124088","article-title":"Searching for the novel specific pre dictors of prostate cancer in urine: the analysis of 84 miRNA expression","volume":"19","author":"Lekchnov","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.talanta.2025.129132_bib372","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17111784","article-title":"Prostate cancer detection and prognosis: from prostate specific antigen (PSA) to exosomal biomarkers","volume":"17","author":"Filella","year":"2016","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.talanta.2025.129132_bib373","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.12381","article-title":"LncRNA-ATB: an indispensable cancer-related long noncoding RNA","volume":"50","author":"Li","year":"2017","journal-title":"Cell Prolif."},{"issue":"22","key":"10.1016\/j.talanta.2025.129132_bib374","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20225758","article-title":"Long noncoding RNA (lncRNA) mediated competing endogenous RNA networks provide novel potential bio markers and therapeutic targets for colorectal cancer","volume":"20","author":"Wang","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.talanta.2025.129132_bib375","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12282-017-0793-9","article-title":"CircRNA: a novel type of biomarker for cancer","volume":"25","author":"Zhang","year":"2018","journal-title":"Breast Cancer"},{"issue":"1","key":"10.1016\/j.talanta.2025.129132_bib376","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12943-017-0663-2","article-title":"CircRNA: functions and properties of a novel potential biomarker for cancer","volume":"16","author":"Meng","year":"2017","journal-title":"Mol. Cancer"},{"issue":"11","key":"10.1016\/j.talanta.2025.129132_bib377","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s12032-019-1317-6","article-title":"SOX4 is activated by C-MYC in prostate cancer","volume":"36","author":"Dong","year":"2019","journal-title":"Med. Oncol."},{"issue":"14","key":"10.1016\/j.talanta.2025.129132_bib378","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1002\/pros.23034","article-title":"Proteomics analysis of malignant and benign prostate tissue by 2D DIGE\/MS reveals new insights into proteins involved in prostate cancer","volume":"75","author":"Davalieva","year":"2015","journal-title":"Prostate"},{"issue":"7","key":"10.1016\/j.talanta.2025.129132_bib379","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1074\/mcp.RA119.001496","article-title":"Proteomic profiling of human prostate cancer-associated fibroblasts (CAF) reveals LOXL2-dependent regulation of the tumor microenvironment","volume":"18","author":"Nguyen","year":"2019","journal-title":"Mol. Cell. Proteomics"},{"issue":"1","key":"10.1016\/j.talanta.2025.129132_bib380","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/14789450.2018.1417846","article-title":"Prostate cancer proteomics: clinically useful protein biomarkers and future perspectives","volume":"15","author":"Intasqui","year":"2018","journal-title":"Expert Rev. Proteomics"},{"issue":"11","key":"10.1016\/j.talanta.2025.129132_bib381","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0224148","article-title":"Integrative proteomic and phosphoproteomic profiling of prostate cell lines","volume":"14","author":"Katsogiannou","year":"2019","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.talanta.2025.129132_bib382","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1161\/CIRCRESAHA.118.310998","article-title":"Epigenomics: technologies and applications","volume":"122","author":"Wang","year":"2018","journal-title":"Circ. Res."},{"issue":"1","key":"10.1016\/j.talanta.2025.129132_bib383","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1158\/1055-9965.EPI-18-0491","article-title":"Epigenetically silenced can didate tumor suppressor genes in prostate cancer: identified by modeling methy lation stratification and applied to progression prediction","volume":"28","author":"Zhang","year":"2019","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"issue":"14","key":"10.1016\/j.talanta.2025.129132_bib384","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1002\/cncr.30045","article-title":"Prostate tumor DNA methylation is associated with cigarette smoking and adverse prostate cancer outcomes","volume":"122","author":"Shui","year":"2016","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.talanta.2025.129132_bib385","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1158\/0008-5472.CAN-15-3278","article-title":"DNA methylation in cancer and aging","volume":"76","author":"Klutstein","year":"2016","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.talanta.2025.129132_bib386","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/npp.2012.112","article-title":"DNA methylation and its basic function","volume":"38","author":"Moore","year":"2013","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/j.talanta.2025.129132_bib387","doi-asserted-by":"crossref","first-page":"657","DOI":"10.2217\/epi.10.44","article-title":"Molecular coupling of DNA methylation and histone methylation","volume":"2","author":"Hashimoto","year":"2010","journal-title":"Epigenomics"},{"issue":"6","key":"10.1016\/j.talanta.2025.129132_bib388","first-page":"620","article-title":"Regulators of gene expression as biomarkers for prostate cancer","volume":"2","author":"Willard","year":"2012","journal-title":"Am. J. Cancer Res."},{"issue":"12","key":"10.1016\/j.talanta.2025.129132_bib389","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/pros.22833","article-title":"A DNA hypermethylation profile reveals new potential biomarkers for prostate cancer diagnosis and prognosis","volume":"74","author":"Ashour","year":"2014","journal-title":"Prostate"},{"issue":"4","key":"10.1016\/j.talanta.2025.129132_bib390","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1007\/s12253-018-0479-4","article-title":"C MYC, HIF-1\u03b1, ERG, TKT, and GSTP1: an axis in prostate cancer?","volume":"25","author":"Boldrini","year":"2019","journal-title":"Pathol. Oncol. Res."},{"issue":"2","key":"10.1016\/j.talanta.2025.129132_bib391","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nm.2284","article-title":"The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44","volume":"17","author":"Liu","year":"2011","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.talanta.2025.129132_bib392","article-title":"Vitamin a and apoptosis in prostate cancer","volume":"9","author":"Zhang","year":"2002","journal-title":"Endocr. Relat. Cancer"},{"issue":"12","key":"10.1016\/j.talanta.2025.129132_bib393","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1158\/0008-5472.CAN-15-3278","article-title":"DNA methylation in cancer and aging","volume":"76","author":"Klutstein","year":"2016","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.talanta.2025.129132_bib394","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2217\/epi-2018-0153","article-title":"DNA methylation of shelf, shore and open sea CpG positions distinguish high microsatellite instability from low or stable microsatellite status colon cancer stem cells","volume":"11","author":"Visone","year":"2019","journal-title":"Epigenomics"},{"issue":"1","key":"10.1016\/j.talanta.2025.129132_bib395","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3892\/ijo.2017.4017","article-title":"Effects of genistein supplementation on genome-wide DNA methylation and gene expression in patients with localized prostate cancer","volume":"51","author":"Bilir","year":"2017","journal-title":"Int. J. Oncol."},{"issue":"5","key":"10.1016\/j.talanta.2025.129132_bib396","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2019.01.031","article-title":"Combining urinary DNA methylation and cell-free microRNA biomarkers for im proved monitoring of prostate cancer patients on active surveillance","volume":"37","author":"Zhao","year":"2019","journal-title":"Urol. Oncol."},{"issue":"9","key":"10.1016\/j.talanta.2025.129132_bib397","doi-asserted-by":"crossref","DOI":"10.2217\/epi-2018-0172","article-title":"Comprehensive mapping of the methylation landscape of 16 CpG-dense regions in oral and pharyngeal squamous cell carcinoma","volume":"11","author":"Langevin","year":"2019","journal-title":"Epigenomics"},{"issue":"2","key":"10.1016\/j.talanta.2025.129132_bib398","first-page":"67","article-title":"The role of artificial intelligence in healthcare","volume":"45","author":"Smith","year":"2020","journal-title":"J. Med. Technol."},{"issue":"7639","key":"10.1016\/j.talanta.2025.129132_bib399","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature21056","article-title":"Dermatologist-level classification of skin cancer with deep neural networks","volume":"542","author":"Esteva","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.talanta.2025.129132_bib400","series-title":"Artificial Intelligence: a Modern Approach","author":"Russell Stuart","year":"2009"},{"issue":"6","key":"10.1016\/j.talanta.2025.129132_bib401","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s12553-022-00708-0","article-title":"Regulatory considerations on the use of machine learning based tools in clinical trials","volume":"12","author":"Massella","year":"2022","journal-title":"Health Technol."},{"issue":"1","key":"10.1016\/j.talanta.2025.129132_bib402","first-page":"118","article-title":"Innovations in AI-powered healthcare: transforming cancer treatment with innovative methods","volume":"3","author":"Rasool","year":"2024","journal-title":"BULLET: Jurnal Multidisiplin Ilmu."},{"issue":"6","key":"10.1016\/j.talanta.2025.129132_bib403","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1007\/s00261-019-01929-0","article-title":"Deep learning and radiomics: the utility of Google TensorFlow Inception in classifying clear cell renal cell carcinoma and oncocytoma on multiphasic CT","volume":"44","author":"Coy","year":"2019","journal-title":"Abdom Radiol"},{"key":"10.1016\/j.talanta.2025.129132_bib404","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s13671-019-00267-0","article-title":"Artificial intelligence in skin cancer","volume":"8","author":"Reiter","year":"2019","journal-title":"Curr. Dermatol. Rep."},{"key":"10.1016\/j.talanta.2025.129132_bib405","first-page":"1","article-title":"An overview of current and emerging diagnostic, staging and prognostic markers for prostate cancer","author":"Bronimann","year":"2020","journal-title":"Expert Rev. Mol. Diagn."},{"key":"10.1016\/j.talanta.2025.129132_bib406","doi-asserted-by":"crossref","first-page":"183","DOI":"10.5152\/dir.2019.19125","article-title":"Artificial intelligence at the intersection of pathology and radiology in prostate cancer","volume":"25","author":"Harmon","year":"2019","journal-title":"Diagn. Interv. Radiol."},{"key":"10.1016\/j.talanta.2025.129132_bib407","doi-asserted-by":"crossref","first-page":"620","DOI":"10.6004\/jnccn.2018.0036","article-title":"NCCN guidelines updates: prostate cancer and prostate cancer early detection","volume":"16","author":"Carroll","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.talanta.2025.129132_bib408","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3233\/CBM-170643","article-title":"Prostate cancer detection using machine learning techniques by employing combination of features extracting strategies","volume":"21","author":"Hussain","year":"2018","journal-title":"Cancer Biomark"},{"key":"10.1016\/j.talanta.2025.129132_bib409","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1002\/jmri.26047","article-title":"Computer-aided diagnosis of prostate cancer using a deep convolutional neural network from multiparametric MRI","volume":"48","author":"Song","year":"2018","journal-title":"J. Magn. Reson. Imaging"},{"key":"10.1016\/j.talanta.2025.129132_bib410","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/MOU.0000000000000040","article-title":"Can MRI replace serial biop sies in men on active surveillance for prostate cancer?","volume":"24","author":"Moore","year":"2014","journal-title":"Curr. Opin. Urol."},{"key":"10.1016\/j.talanta.2025.129132_bib411","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/jmri.20251","article-title":"Differentiation of noncan cerous tissue and cancer lesions by apparent diffusion coefficient values in transition and peripheral zones of the prostate","volume":"21","author":"Sato","year":"2005","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/j.talanta.2025.129132_bib412","doi-asserted-by":"crossref","first-page":"E6265","DOI":"10.1073\/pnas.1505935112","article-title":"Automatic classification of prostate cancer Gleason scores from multiparametric magnetic resonance images","volume":"112","author":"Fehr","year":"2015","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.talanta.2025.129132_bib413","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0217702","article-title":"Radiomics and machine learning of multisequence multiparametric prostate MRI: towards improved non-invasive prostate cancer characterization","volume":"14","author":"Toivonen","year":"2019","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.talanta.2025.129132_bib414","doi-asserted-by":"crossref","first-page":"432","DOI":"10.21037\/tcr.2016.06.20","article-title":"Prostate cancer radiomics and the promise of radiog enomics","volume":"5","author":"Stoyanova","year":"2016","journal-title":"Transl. Cancer Res."},{"issue":"1","key":"10.1016\/j.talanta.2025.129132_bib415","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/s41598-022-04951-3","article-title":"A data-driven ultrasound approach dis criminates pathological high grade prostate cancer","volume":"12","author":"Akatsuka","year":"2022","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.talanta.2025.129132_bib416","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1007\/s00330-019-06436-w","article-title":"Automated multiparametric localization of pros tate cancer based on B-mode, shear-wave elastography, and con trast-enhanced ultrasound radiomics","volume":"30","author":"Wildeboer","year":"2020","journal-title":"Eur. Radiol."},{"issue":"6","key":"10.1016\/j.talanta.2025.129132_bib417","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1097\/MOU.0000000000000813","article-title":"Pathomics in urology","volume":"30","author":"Schuettfort","year":"2020","journal-title":"Curr. Opin. Urol."},{"issue":"1","key":"10.1016\/j.talanta.2025.129132_bib418","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-30535-1","article-title":"Automated Gleason grading of pros tate cancer tissue microarrays via deep learning","volume":"8","author":"Arvaniti","year":"2018","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.talanta.2025.129132_bib419","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S1470-2045(19)30739-9","article-title":"Automated deep-learning system for Gleason grading of prostate cancer using biopsies: a diagnostic study","volume":"21","author":"Bulten","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.talanta.2025.129132_bib420","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1259\/bjr\/56357549","article-title":"Applications of transrectal ultrasound in prostate cancer","volume":"85","author":"Harvey","year":"2012","journal-title":"Br. J. Radiol."},{"key":"10.1016\/j.talanta.2025.129132_bib421","first-page":"1395","article-title":"Combining artificial neural networks and transrectal ultrasound in the diagnosis of prostate cancer","volume":"17","author":"Porter","year":"2003","journal-title":"Oncology"},{"key":"10.1016\/j.talanta.2025.129132_bib422","article-title":"MRI\/Transrectal ultrasound fusion-guided targeted biopsy and transrectal ultrasound-guided systematic biopsy for diagnosis of prostate cancer: a systematic review and meta-analysis","volume":"12","author":"Xie","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.talanta.2025.129132_bib423","doi-asserted-by":"crossref","DOI":"10.1177\/1756287220916613","article-title":"The role of MRI\/TRUS fusion biopsy in the diagnosis of clinically significant prostate cancer","volume":"12","author":"Benelli","year":"2020","journal-title":"Ther. Adv. Urol."},{"key":"10.1016\/j.talanta.2025.129132_bib424","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.euf.2019.04.009","article-title":"DeepLearning for Real-Time, automatic, and scanner-adapted prostate (Zone) segmentation of transrectal ultrasound, for example, magnetic resonance imaging\u2013transrectal ultrasound fusion prostate biopsy","volume":"7","author":"Van Sloun","year":"2021","journal-title":"Eur. Urol. Focus"},{"key":"10.1016\/j.talanta.2025.129132_bib425","unstructured":"National Cancer Institute. Surveillance, Epidemoiology, and End Results Program (SEER). Cancer Stat Facts: Prostate Cancer. Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/prost.html."},{"key":"10.1016\/j.talanta.2025.129132_bib426","article-title":"Evolving natural history of metastatic prostate cancer","volume":"12","author":"Nafissi","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.talanta.2025.129132_bib427","first-page":"6357","article-title":"Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer","volume":"9","author":"Ross","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.talanta.2025.129132_bib430","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen pet-ct in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (propsma): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.talanta.2025.129132_bib431","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature14539","article-title":"Deep learning","volume":"521","author":"LeCun","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.talanta.2025.129132_bib432","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/9640177","article-title":"3d convolutional neural network framework with deep learning for nuclear medicine","volume":"2022","author":"Manimegalai","year":"2022","journal-title":"Scanning"},{"key":"10.1016\/j.talanta.2025.129132_bib433","series-title":"Tnm Classification of Malignant Tumours","author":"Brierley","year":"2017"},{"key":"10.1016\/j.talanta.2025.129132_bib434","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1097\/MOU.0000000000000814","article-title":"Uro-technology and SoMe working group of the young academic urologists working party of the European association of urology applications of neural networks in urology: a systematic review","volume":"30","author":"Checcucci","year":"2020","journal-title":"Curr. Opin. Urol."},{"key":"10.1016\/j.talanta.2025.129132_bib435","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s11548-015-1305-z","article-title":"Surgical robotics beyond enhanced dexterity instrumentation: a survey of machine learning techniques and their role in intelligent and autonomous surgical actions","volume":"11","author":"Kassahun","year":"2016","journal-title":"Int. J. Comput. Assist. Radiol. Surg."},{"key":"10.1016\/j.talanta.2025.129132_bib436","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1109\/TMI.2017.2665671","article-title":"Detection and localization of robotic tools in robot-assisted surgery videos using deep neural networks for Region proposal and detection","volume":"36","author":"Sarikaya","year":"2017","journal-title":"IEEE Trans. Med. Imaging"},{"key":"10.1016\/j.talanta.2025.129132_bib437","doi-asserted-by":"crossref","first-page":"529.e1","DOI":"10.1016\/j.urolonc.2018.08.012","article-title":"Robotic assisted vs. open radical prostatectomy: a machine learning framework for intelligent analysis of patient-reported outcomes from online cancer support groups","volume":"36","author":"Ranasinghe","year":"2018","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.talanta.2025.129132_bib438","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/bju.14477","article-title":"Use of machine learning to predict early biochemical recurrence after robot-assisted prostatectomy","volume":"123","author":"Wong","year":"2019","journal-title":"BJU Int."},{"key":"10.1016\/j.talanta.2025.129132_bib439","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1001\/jamasurg.2018.1512","article-title":"Automated performance metrics and machine learning algorithms to measure surgeon performance and anticipate clinical outcomes in robotic surgery","volume":"153","author":"Hung","year":"2018","journal-title":"JAMA Surg."},{"key":"10.1016\/j.talanta.2025.129132_bib440","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/s41585-019-0193-3","article-title":"A new era: artificial intelligence and machine learning in prostate cancer","volume":"16","author":"Goldenberg","year":"2019","journal-title":"Nat. Rev. Urol."},{"issue":"1","key":"10.1016\/j.talanta.2025.129132_bib441","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1148\/radiol.2018173064","article-title":"Radiomic machine learning for characterization of prostate lesions with MRI: comparison to ADC values","volume":"289","author":"Bonekamp","year":"2018","journal-title":"Radiology"},{"issue":"4","key":"10.1016\/j.talanta.2025.129132_bib442","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41391-018-0067-4","article-title":"Development and validation of a novel automated Gleason grade and molecular profile that define a highly predictive prostate cancer progression algorithm-based test","volume":"21","author":"Donovan","year":"2018","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"1","key":"10.1016\/j.talanta.2025.129132_bib443","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-30535-1","article-title":"Automated Gleason grading of prostate cancer tissue microarrays via deep learning","volume":"8","author":"Arvaniti","year":"2018","journal-title":"Sci. Rep."},{"issue":"109918","key":"10.1016\/j.talanta.2025.129132_bib444","article-title":"Potential of AI and ML in oncology research including diagnosis, treatment and future directions: a comprehensive prospective","volume":"189","author":"Gupta","year":"2025","journal-title":"Comput. Biol. Med."},{"issue":"5","key":"10.1016\/j.talanta.2025.129132_bib445","first-page":"E145","article-title":"Prediction of prostate cancer by deep learning with multilayer artifcial neural network","volume":"13","author":"Takeuchi","year":"2019","journal-title":"Can Urol Assoc J"},{"issue":"1","key":"10.1016\/j.talanta.2025.129132_bib446","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1148\/radiol.2018173064","article-title":"Radiomic machine learning for characterization of prostate lesions with MRI: comparison to ADC values","volume":"289","author":"Bonekamp","year":"2018","journal-title":"Radiology"},{"issue":"6","key":"10.1016\/j.talanta.2025.129132_bib447","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.eururo.2018.09.050","article-title":"askMUSIC: leveraging a clinical registry to develop a new machine learning model to inform patients of prostate cancer treatments chosen by similar men","volume":"75","author":"Aufenberg","year":"2019","journal-title":"Eur. Urol."},{"issue":"6","key":"10.1016\/j.talanta.2025.129132_bib448","first-page":"555","article-title":"Machine learning-based radiomic models to predict intensity-modulated radiation therapy response, Gleason score and stage in prostate cancer, Radiol","volume":"124","author":"Abdollahi","year":"2019","journal-title":"Med"},{"issue":"5","key":"10.1016\/j.talanta.2025.129132_bib449","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1089\/end.2018.0035","article-title":"Utilizing machine learning and automated performance metrics to evaluate robot-assisted radical prostatectomy performance and predict outcomes","volume":"32","author":"Hung","year":"2018","journal-title":"J. Endourol."},{"issue":"3","key":"10.1016\/j.talanta.2025.129132_bib450","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/bju.14735","article-title":"A deep-learning model using automated performance metrics and clinical features to predict urinary continence recovery after robot-assisted radical prostatectomy","volume":"124","author":"Hung","year":"2019","journal-title":"BJU Int."},{"issue":"1","key":"10.1016\/j.talanta.2025.129132_bib451","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/bju.14477","article-title":"Use of machine learning to predict early biochemical recurrence after robot-assisted prostatectomy","volume":"123","author":"Wong","year":"2019","journal-title":"BJU Int."},{"issue":"1","key":"10.1016\/j.talanta.2025.129132_bib452","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/pros.2990020105","article-title":"The zonal anatomy of the prostate","volume":"2","author":"McNeal","year":"1981","journal-title":"Prostate"},{"issue":"21","key":"10.1016\/j.talanta.2025.129132_bib453","doi-asserted-by":"crossref","first-page":"5417","DOI":"10.3390\/cancers13215417","article-title":"Androgen receptor signaling in prostate cancer and therapeutic strategies","volume":"13","author":"Jacob","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.talanta.2025.129132_bib454","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/DDDT.S15850","article-title":"Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer","volume":"6","author":"Rehman","year":"2012","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.talanta.2025.129132_bib455","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"DeBono","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.talanta.2025.129132_bib456","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.eururo.2017.03.007","article-title":"Clinical outcomes from androgen signaling-directed therapy after treatment with abiraterone acetate and prednisone in patients with metastatic castration-resistant prostate cancer: post hoc analysis of COU-AA-302","volume":"72","author":"Smith","year":"2017","journal-title":"Eur. Urol."},{"key":"10.1016\/j.talanta.2025.129132_bib457","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.talanta.2025.129132_bib458","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.talanta.2025.129132_bib459","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1200\/JCO.2016.70.1961","article-title":"Clinical significance of androgen receptor splice Variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with First- and second-line abiraterone and enzalutamide","volume":"35","author":"Antonarakis","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.talanta.2025.129132_bib460","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1200\/JCO.18.01731","article-title":"Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the PROPHECY study","volume":"37","author":"Armstrong","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.talanta.2025.129132_bib461","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1158\/1078-0432.CCR-20-4616","article-title":"Phase II multicenter study of enzalutamide in metastatic castration-resistant prostate cancer to identify mechanisms driving resistance","volume":"27","author":"McKay","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.talanta.2025.129132_bib462","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1200\/JCO.21.00169","article-title":"Prospective evaluation of clinical outcomes using a multiplex liquid biopsy targeting diverse resistance mechanisms in metastatic prostate cancer","volume":"39","author":"Sperger","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.talanta.2025.129132_bib463","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1093\/annonc\/mdy406","article-title":"Development and validation of a prognostic model for overall survival in chemotherapy-na\u00efve men with metastatic castration-resistant prostate cancer","volume":"29","author":"Armstrong","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.talanta.2025.129132_bib464","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1158\/0008-5472.CAN-11-3892","article-title":"Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer","volume":"72","author":"Hu","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.talanta.2025.129132_bib465","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1158\/0008-5472.CAN-12-3630","article-title":"Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines","volume":"73","author":"Li","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.talanta.2025.129132_bib466","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41419-020-02932-w","article-title":"The miR-361-3p increases enzalutamide (Enz) sensitivity via targeting the ARv7 and MKNK2 to better suppress the enz-resistant prostate cancer","volume":"11","author":"Liu","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.talanta.2025.129132_bib467","doi-asserted-by":"crossref","first-page":"5379","DOI":"10.1038\/s41388-021-01914-2","article-title":"ARVib suppresses growth of advanced prostate cancer via inhibition of androgen receptor signaling","volume":"40","author":"Liu","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.talanta.2025.129132_bib468","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1158\/1535-7163.MCT-20-0015","article-title":"Cross resistance among next-generation antiandrogen drugs through the AKR1C3\/AR-V7 axis in advanced prostate cancer","volume":"19","author":"Zhao","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.talanta.2025.129132_bib469","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1158\/1535-7163.MCT-18-1322","article-title":"AKR1C3 promotes AR-V7 protein stabilization and confers resistance to AR-Targeted therapies in advanced prostate cancer","volume":"18","author":"Liu","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.talanta.2025.129132_bib470","author":"Parikh"},{"key":"10.1016\/j.talanta.2025.129132_bib471","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1158\/2159-8290.CD-13-0226","article-title":"A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509","volume":"3","author":"Joseph","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.talanta.2025.129132_bib472","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1158\/2159-8290.CD-13-0142","article-title":"An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide)","volume":"3","author":"Korpal","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.talanta.2025.129132_bib473","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.3390\/cancers13122939","article-title":"Evaluation of darolutamide (ODM201) efficiency on androgen receptor mutants reported to date in prostate cancer patients","volume":"13","author":"Lallous","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.talanta.2025.129132_bib474","doi-asserted-by":"crossref","first-page":"R146","DOI":"10.1530\/EC-17-0118","article-title":"Clinical relevance of androgen receptor alterations in prostate cancer","volume":"6","author":"Jernberg","year":"2017","journal-title":"Endocr. Connect."},{"key":"10.1016\/j.talanta.2025.129132_bib475","first-page":"316","article-title":"Current understanding of resistance to abiraterone and enzalutamide in advanced prostate cancer","volume":"14","author":"Antonarakis","year":"2016","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"10.1016\/j.talanta.2025.129132_bib476","first-page":"803","article-title":"Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays","volume":"59","author":"Bubendorf","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.talanta.2025.129132_bib477","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.humpath.2006.09.008","article-title":"Androgen receptor amplification is associated with increased cell proliferation in prostate cancer","volume":"38","author":"Haapala","year":"2007","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.talanta.2025.129132_bib478","first-page":"3550","article-title":"Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer","volume":"61","author":"Linja","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.talanta.2025.129132_bib479","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ccr.2010.05.026","article-title":"Integrative genomic profiling of human prostate cancer","volume":"18","author":"Taylor","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.talanta.2025.129132_bib480","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/ng0495-401","article-title":"In vivo amplification of the androgen receptor gene and progression of human prostate cancer","volume":"9","author":"Visakorpi","year":"1995","journal-title":"Nat. Genet."},{"key":"10.1016\/j.talanta.2025.129132_bib481","doi-asserted-by":"crossref","first-page":"8141","DOI":"10.1158\/0008-5472.CAN-09-0919","article-title":"Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens","volume":"69","author":"Waltering","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.talanta.2025.129132_bib482","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13550-018-0451-z","article-title":"Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer","volume":"8","author":"L\u00fcckerath","year":"2018","journal-title":"EJNMMI Res."},{"key":"10.1016\/j.talanta.2025.129132_bib483","doi-asserted-by":"crossref","first-page":"9578","DOI":"10.1073\/pnas.1106383108","article-title":"Noninvasive mea surement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen","volume":"108","author":"Evans","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.talanta.2025.129132_bib484","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.2967\/jnumed.117.192476","article-title":"Impact of (68)Ga-PSMA-11 PET on management in patients with biochemically recurrent prostate cancer","volume":"58","author":"Hope","year":"2017","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.talanta.2025.129132_bib485","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.euo.2018.03.010","article-title":"Heterogeneous flare in prostate-specific membrane antigen positron emission tomography tracer uptake with initiation of androgen pathway blockade in metastatic prostate cancer","volume":"1","author":"Aggarwal","year":"2018","journal-title":"Eur. Urol. Oncol."},{"key":"10.1016\/j.talanta.2025.129132_bib486","doi-asserted-by":"crossref","first-page":"950","DOI":"10.2967\/jnumed.118.223099","article-title":"Rapid modulation of PSMA expression by androgen deprivation: serial (68)Ga-PSMA-11 PET in men with hormone-sensitive and castrate-resistant prostate cancer commencing androgen blockade","volume":"60","author":"Emmett","year":"2019","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.talanta.2025.129132_bib487","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00259-019-04674-0","article-title":"New insights in the paradigm of upregulation of tumoral PSMA expression by androgen receptor blockade: enzalutamide induces PSMA upregulation in castration-resistant prostate cancer even in patients having previously progressed on enzalutamide","volume":"47","author":"Rosar","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.talanta.2025.129132_bib489","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1200\/JCO.20.02759","article-title":"TRANSFORMER: a randomized phase II study comparing bipolar androgen therapy versus enzalutamide in asymptomatic men with castration-resistant metastatic prostate cancer","volume":"39","author":"Denmeade","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.talanta.2025.129132_bib490","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1158\/1078-0432.CCR-14-2666","article-title":"Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance in castration-resistant prostate cancer","volume":"21","author":"Azad","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"14","key":"10.1016\/j.talanta.2025.129132_bib491","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1002\/pros.20995","article-title":"Effects of EGFR tyrosine kinase inhibitor erlotinib in prostate cancer cells in vitro: Erlotinib effectiveness in prostate cancer cells","volume":"69","author":"Festuccia","year":"2009","journal-title":"Prostate"},{"issue":"3","key":"10.1016\/j.talanta.2025.129132_bib492","doi-asserted-by":"crossref","first-page":"167","DOI":"10.4155\/tde-2021-0060","article-title":"Targeting the IGF-1R in prostate and colorectal cancer: reasons behind trial failure and future directions","volume":"13","author":"Tufail","year":"2022","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.talanta.2025.129132_bib493","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/1097-0045(20001101)45:3<216::AID-PROS3>3.0.CO;2-C","article-title":"Vascular endothelial growth factor and its correlation with angiogenesis and P53 expression in prostate cancer","volume":"45","author":"Strohmeyer","year":"2000","journal-title":"Prostate"},{"key":"10.1016\/j.talanta.2025.129132_bib494","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0090-4295(99)00167-3","article-title":"Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer","volume":"54","author":"Duque","year":"1999","journal-title":"Urology"},{"key":"10.1016\/j.talanta.2025.129132_bib495","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/pros.10025","article-title":"Thrombospondin-1, vascular endothelial growth factor and fibroblast growth Factor-2 are key functional regulators of angiogenesis in the prostate","volume":"49","author":"Doll","year":"2001","journal-title":"Prostate"},{"key":"10.1016\/j.talanta.2025.129132_bib496","first-page":"1882","article-title":"Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting","volume":"6","author":"Borre","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.talanta.2025.129132_bib497","first-page":"2533","article-title":"Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and Leukemia Group B Study","volume":"61","author":"Bok","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.talanta.2025.129132_bib498","first-page":"1655","article-title":"Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion Molecule-1 with lymph node status and biochemical progression after radical prostatectomy","volume":"22","author":"Shariat","year":"2004","journal-title":"J. Clin. Orthod."},{"key":"10.1016\/j.talanta.2025.129132_bib499","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.3390\/cancers12092382","article-title":"Angiogenesis inhibition in prostate cancer: an update","volume":"12","author":"Sarkar","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.talanta.2025.129132_bib500","first-page":"1534","article-title":"Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without Bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401","volume":"30","author":"Kelly","year":"2012","journal-title":"J. Clin. Orthod."},{"key":"10.1016\/j.talanta.2025.129132_bib501","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S1470-2045(13)70184-0","article-title":"Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial","volume":"14","author":"Tannock","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.talanta.2025.129132_bib502","first-page":"76","article-title":"Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant","volume":"32","author":"Michaelson","year":"2014","journal-title":"Prostate Cancer. JCO"},{"key":"10.1016\/j.talanta.2025.129132_bib503","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1470-2045(15)70025-2","article-title":"Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"16","author":"Petrylak","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.talanta.2025.129132_bib504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2020\/6820241","article-title":"Comprehensive biological and clinical perspective can drive a patient-tailored approach to multiple myeloma: bridging the gaps between the plasma cell and the neoplastic niche","volume":"2020","author":"Solimando","year":"2020","journal-title":"J. Oncol."},{"issue":"9","key":"10.1016\/j.talanta.2025.129132_bib505","doi-asserted-by":"crossref","first-page":"20563","DOI":"10.18632\/oncotarget.25003","article-title":"Inhibition of MTOR complex 2 restrains tumor angiogenesis in multiple myeloma","author":"Lamanuzzi","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.talanta.2025.129132_bib506","doi-asserted-by":"crossref","first-page":"997","DOI":"10.3390\/jcm8070997","article-title":"High-risk multiple myeloma: integrated clinical and omics approach dissects the neoplastic clone and the tumor microenvironment","volume":"8","author":"Solimando","year":"2019","journal-title":"JCM"},{"key":"10.1016\/j.talanta.2025.129132_bib507","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1002\/cncr.30585","article-title":"Lenalidomide use in myelodysplastic syndromes: insights into the biologic mechanisms and clinical applications: use of lenalidomide in MDS: biology and efficacy","volume":"123","author":"Stahl","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.talanta.2025.129132_bib508","first-page":"412","article-title":"Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial","volume":"31","author":"Smith","year":"2013","journal-title":"J. Clin. Orthod."},{"key":"10.1016\/j.talanta.2025.129132_bib509","series-title":"Proceedings of the Therapeutic Agents: Small Molecule Kinase Inhibitors","first-page":"A233","article-title":"Abstract A233: cabozantinib (XL184), a dual MET-VEGFR2 inhibitor, blocks osteoblastic and osteolytic progression of human prostate cancer xenografts in mouse bone","author":"Schimmoller","year":"2011"},{"key":"10.1016\/j.talanta.2025.129132_bib510","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","volume":"10","author":"Yakes","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.talanta.2025.129132_bib511","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1158\/2159-8290.CD-11-0240","article-title":"Suppression of tumor invasion and metastasis by concurrent inhibition of C-Met and VEGF signaling in pancreatic neuroendocrine tumors","volume":"2","author":"Sennino","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.talanta.2025.129132_bib512","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0078881","article-title":"Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling","volume":"8","author":"Nguyen","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.talanta.2025.129132_bib513","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1158\/1078-0432.CCR-13-0839","article-title":"Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions","volume":"20","author":"Dai","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.talanta.2025.129132_bib514","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju033","article-title":"Preclinical evaluation of imaging biomarkers for prostate cancer bone metastasis and response to cabozantinib","volume":"106","author":"Graham","year":"2014","journal-title":"JNCI: J Natl Cancer Institute"},{"key":"10.1016\/j.talanta.2025.129132_bib515","first-page":"2033","article-title":"Antitumor agent cabozantinib decreases RANKL expression in osteoblastic cells and inhibits osteoclastogenesis and PTHrP-Stimulated bone resorption: cabozantinib and the bone microenvironment","author":"Stern","year":"2014","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.talanta.2025.129132_bib516","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1476-4598-9-9","article-title":"Vascular endothelial growth factor regulates myeloid cell Leukemia-1 expression through Neuropilin-1-Dependent activation of C-MET signaling in human prostate cancer cells","volume":"9","author":"Zhang","year":"2010","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.talanta.2025.129132_bib517","first-page":"3391","article-title":"Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study","volume":"32","author":"Smith","year":"2014","journal-title":"J. Clin. Orthod."},{"key":"10.1016\/j.talanta.2025.129132_bib518","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.eururo.2014.02.013","article-title":"Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort","volume":"67","author":"Basch","year":"2015","journal-title":"Eur. Urol."},{"key":"10.1016\/j.talanta.2025.129132_bib519","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1158\/1078-0432.CCR-13-0319","article-title":"A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases","volume":"19","author":"Lee","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.talanta.2025.129132_bib520","first-page":"3005","article-title":"Phase III study of cabozantinib in previously treated metastatic castration-resistant prostate cancer: comet-1","volume":"34","author":"Smith","year":"2016","journal-title":"J. Clin. Orthod."},{"key":"10.1016\/j.talanta.2025.129132_bib521","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: therapeutic implications","volume":"285","author":"Sherwood","year":"1971","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.talanta.2025.129132_bib522","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.3390\/cancers12113380","article-title":"Cancer-associated angiogenesis: the endothelial cell as a checkpoint for immunological patrolling","volume":"12","author":"Solimando","year":"2020","journal-title":"Cancers"},{"issue":"106588","key":"10.1016\/j.talanta.2025.129132_bib523","article-title":"PSA, an outdated biomarker for prostate cancer: in search of a more specific biomarker, citrate takes the spotlight","volume":"243","author":"Galey","year":"2024","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.talanta.2025.129132_bib524","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.ccr.2011.04.008","article-title":"Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer","volume":"19","author":"Carver","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.talanta.2025.129132_bib525","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1158\/1535-7163.MCT-13-0032","article-title":"Synergistic targeting of PI3K\/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo","volume":"12","author":"Thomas","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.talanta.2025.129132_bib526","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1200\/jco.2011.29.15_suppl.3003","article-title":"Safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of the oral AKT inhibitor GSK2141795 (GSK795) in a phase I first-in-human study","volume":"29","author":"Burris","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.talanta.2025.129132_bib527","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1200\/JCO.2011.36.1360","article-title":"Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors","volume":"30","author":"Bendell","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.talanta.2025.129132_bib528","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2017.02.030","article-title":"Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer","volume":"81","author":"Armstrong","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.talanta.2025.129132_bib529","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1158\/0008-5472.CAN-05-4000","article-title":"Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer","volume":"66","author":"Stanbrough","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.talanta.2025.129132_bib530","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1158\/0008-5472.CAN-08-0249","article-title":"Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth","volume":"68","author":"Montgomery","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.talanta.2025.129132_bib531","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1158\/0008-5472.CAN-08-0249","article-title":"Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth","volume":"68","author":"Montgomery","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.talanta.2025.129132_bib532","doi-asserted-by":"crossref","first-page":"6142","DOI":"10.1158\/0008-5472.CAN-12-1335","article-title":"Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors","volume":"72","author":"Mitsiades","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.talanta.2025.129132_bib533","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(21)00580-8","article-title":"Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial","volume":"398","author":"Sweeney","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.talanta.2025.129132_bib534","first-page":"2395","article-title":"Sustained in vivo regression of dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555)","volume":"59","author":"George","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.talanta.2025.129132_bib535","doi-asserted-by":"crossref","first-page":"5009","DOI":"10.1200\/JCO.2019.37.15_suppl.5009","article-title":"Phase 1b\/2 study of enzalutamide (ENZ) with LY3023414 (LY) or placebo (PL) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) after progression on abiraterone","volume":"37","author":"Sweeney","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.talanta.2025.129132_bib536","doi-asserted-by":"crossref","first-page":"5981","DOI":"10.1158\/1078-0432.CCR-17-0725","article-title":"A first-time-in-human study of GSK2636771, a phosphoinositide 3 kinase beta-selective inhibitor, in patients with advanced solid tumors","volume":"23","author":"Mateo","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.talanta.2025.129132_bib537","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/jnci\/92.17.1367","article-title":"Apoptosis: translating theory to therapy for prostate cancer","volume":"92","author":"Isaacs","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.talanta.2025.129132_bib538","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-20-0751","article-title":"Targeting the p300\/CBP axis in lethal prostate cancer","volume":"11","author":"Welti","year":"2021","journal-title":"Cancer Discov."},{"issue":"19","key":"10.1016\/j.talanta.2025.129132_bib541","doi-asserted-by":"crossref","first-page":"4781","DOI":"10.3390\/ijms20194781","article-title":"The need for multi-omics biomarker signatures in precision medicine","volume":"20","author":"Olivier","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.talanta.2025.129132_bib542","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1038\/nm.3686","article-title":"Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development","volume":"20","author":"Mayers","year":"2014","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.talanta.2025.129132_bib543","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12935-018-0676-y","article-title":"Citrate targets FBPase and constitutes an emerging novel approach for cancer therapy","volume":"18","author":"Icard","year":"2018","journal-title":"Cancer Cell Int."},{"issue":"1","key":"10.1016\/j.talanta.2025.129132_bib544","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-018-4437-z","article-title":"Metabolomic profiles in breast cancer: a pilot case-control study in the breast cancer family registry","volume":"18","author":"Dougan","year":"2018","journal-title":"BMC Cancer"},{"issue":"7187","key":"10.1016\/j.talanta.2025.129132_bib545","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nature06913","article-title":"The cancer biomarker problem","volume":"452","author":"Sawyers","year":"2008","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.talanta.2025.129132_bib546","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-020-07058-y","article-title":"Immune landscape of human prostate cancer: immune evasion mechanisms and biomarkers for personalized immunotherapy","volume":"20","author":"Bou-Dargham","year":"2020","journal-title":"BMC Cancer"},{"issue":"24","key":"10.1016\/j.talanta.2025.129132_bib547","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1001\/jama.2017.7248","article-title":"The diagnosis and treatment of prostate cancer: a review","volume":"317","author":"Litwin","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.talanta.2025.129132_bib548","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40880-018-0344-6","article-title":"Liquid biopsy: a powerful tool to monitor trastuzumab resistance in HER2-positive metastatic gastric cancer","volume":"38","author":"Shen","year":"2018","journal-title":"Cancer Commun."},{"issue":"1","key":"10.1016\/j.talanta.2025.129132_bib549","first-page":"11","article-title":"Cancer diagnosis: from tumor to liquid biopsy and beyond","volume":"19","author":"Vaidyanathan","year":"2019","journal-title":"Lab Chip"},{"issue":"1","key":"10.1016\/j.talanta.2025.129132_bib550","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-019-02185-y","article-title":"Multi-omic serum biomarkers for prognosis of disease progression in prostate cancer","volume":"18","author":"Kiebish","year":"2020","journal-title":"J. Transl. Med."},{"issue":"8","key":"10.1016\/j.talanta.2025.129132_bib551","first-page":"1","article-title":"Computational methods and resources for the interpretation of genomic variants in cancer","volume":"16","author":"Tian","year":"2015","journal-title":"BMC Genom."},{"issue":"4","key":"10.1016\/j.talanta.2025.129132_bib552","first-page":"1","article-title":"An ontology-based documentation of data discovery and integration process in cancer outcomes research","volume":"20","author":"Zhang","year":"2020","journal-title":"BMC Med Inform Decis Mak"},{"issue":"1","key":"10.1016\/j.talanta.2025.129132_bib553","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s41232-021-00170-x","article-title":"Single-cell and spatial analyses of cancer cells: toward elucidating the molecular mechanisms of clonal evolution and drug resistance acquisition","volume":"41","author":"Nagasawa","year":"2021","journal-title":"Inflamm. Regen."},{"issue":"4","key":"10.1016\/j.talanta.2025.129132_bib554","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.ccell.2020.03.001","article-title":"Loss of CHD1 promotes heterogeneous mechanisms of resistance to AR-targeted therapy via chromatin dysregulation","volume":"37","author":"Zhang","year":"2020","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.talanta.2025.129132_bib555","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/j.cell.2020.07.032","article-title":"Genome-scale imaging of the 3D organization and transcriptional activity of chromatin","volume":"182","author":"Su","year":"2020","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.talanta.2025.129132_bib556","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/cr.2017.82","article-title":"Single-cell multi-omics sequencing of mouse early embryos and embryonic stem cells","volume":"27","author":"Guo","year":"2017","journal-title":"Cell Res."},{"key":"10.1016\/j.talanta.2025.129132_bib557","doi-asserted-by":"crossref","first-page":"16","DOI":"10.21037\/amj-20-166","article-title":"Robotic surgery in urology: a review from the beginning to the single-site","volume":"7","author":"De Marchi","year":"2022","journal-title":"AME Med. J."},{"key":"10.1016\/j.talanta.2025.129132_bib558","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4103\/0972-9941.65161","article-title":"Ergonomics in laparoscopic surgery","volume":"6","author":"Supe","year":"2010","journal-title":"J. Minim. Access Surg."},{"key":"10.1016\/j.talanta.2025.129132_bib559","article-title":"Retzius-sparing versus standard robotic-assisted laparoscopic prostatectomy for the treatment of clinically localized prostate cancer","volume":"8","author":"Rosenberg","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.talanta.2025.129132_bib560","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.euf.2021.08.003","article-title":"Retzius sparing radical prostatectomy versus robot-assisted radical prostatectomy: which technique is more beneficial for prostate cancer patients (MASTER study)? A systematic review and meta-analysis","volume":"8","author":"Barakat","year":"2022","journal-title":"Eur. Urol. Focus"},{"key":"10.1016\/j.talanta.2025.129132_bib561","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.eururo.2021.07.025","article-title":"Functional and oncological outcomes after open versus robot-assisted laparoscopic radical prostatectomy for localised prostate cancer: 8-year Follow-up","volume":"80","author":"Lantz","year":"2021","journal-title":"Eur. Urol."},{"key":"10.1016\/j.talanta.2025.129132_bib562","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1308\/rcsbull.2020.185","article-title":"Robotic surgery: training, competence assessment and credentialising","volume":"102","author":"Dixon","year":"2020","journal-title":"Bull. R Coll. Surg. Eng."},{"key":"10.1016\/j.talanta.2025.129132_bib563","doi-asserted-by":"crossref","first-page":"204","DOI":"10.4103\/0970-1591.185095","article-title":"Impact of assistant surgeon on outcomes in robotic surgery","volume":"32","author":"Nayyar","year":"2016","journal-title":"Indian J. Urol"},{"key":"10.1016\/j.talanta.2025.129132_bib564","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1515\/med-2016-0055","article-title":"Malfunctions of robotic system in surgery: role and responsibility of surgeon in legal point of view","volume":"11","author":"Ferrarese","year":"2016","journal-title":"Open Med."},{"key":"10.1016\/j.talanta.2025.129132_bib565","doi-asserted-by":"crossref","first-page":"975","DOI":"10.3349\/ymj.2018.59.8.975","article-title":"Efficacy and Safety of Robotic Procedures Performed Using the da Vinci Robotic Surgical System at a Single Institute in Korea: experience with 10000 Cases","volume":"59","author":"Koh","year":"2018","journal-title":"Yonsei Med. J."},{"key":"10.1016\/j.talanta.2025.129132_bib566","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/bja\/aex003","article-title":"Complications of robotic-assisted laparoscopic surgery distant from the surgical site","volume":"118","author":"Maerz","year":"2017","journal-title":"BJA Br. J. Anaesth."},{"key":"10.1016\/j.talanta.2025.129132_bib567","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1089\/end.2013.0623","article-title":"Positioning-related complications of minimally invasive radical prostatectomies","volume":"28","author":"Wen","year":"2014","journal-title":"J. Endourol."},{"key":"10.1016\/j.talanta.2025.129132_bib568","doi-asserted-by":"crossref","first-page":"871","DOI":"10.23736\/S0375-9393.19.13360-3","article-title":"Joint consensus on anesthesia in urologic and gynecologic robotic surgery: specific issues in management from a task force of the SIAARTI, SIGO, and SIU","volume":"85","author":"Aceto","year":"2019","journal-title":"Minerva Anestesiol."},{"key":"10.1016\/j.talanta.2025.129132_bib569","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.surg.2022.04.010","article-title":"The environmental impact of surgery: a systematic review","volume":"172","author":"Shoham","year":"2022","journal-title":"Surgery"},{"key":"10.1016\/j.talanta.2025.129132_bib570","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/bjs\/znac191","article-title":"Environmental sustainability in robotic and laparoscopic surgery: systematic review","volume":"109","author":"Papadopoulou","year":"2022","journal-title":"Br. J. Surg."},{"key":"10.1016\/j.talanta.2025.129132_bib571","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.3390\/jcm11112957","article-title":"Robotic abdominal surgery and COVID-19: a systematic review of published literature and peer-reviewed guidelines during the SARS-CoV-2 pandemic","volume":"11","author":"Fleming","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.talanta.2025.129132_bib573","doi-asserted-by":"crossref","DOI":"10.1002\/rcs.2174","article-title":"Uptake and accessibility of surgical robotics in England","volume":"17","author":"Lam","year":"2021","journal-title":"Int. J. Med. Robot."},{"key":"10.1016\/j.talanta.2025.129132_bib574","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12913-021-06105-z","article-title":"Detailed cost of robotic-assisted surgery in the Australian public health sector: from implementation to a multi-specialty caseload","volume":"21","author":"McBride","year":"2021","journal-title":"BMC Health Serv. Res."},{"key":"10.1016\/j.talanta.2025.129132_bib575","unstructured":"National Institute for Health Care Excellence (NICE). Prostate cancer: diagnosis and management. NICE Guidance 131. Available online: https:\/\/www.nice.org.uk\/guidance\/ng131 (accessed on 14 November 2022)."},{"key":"10.1016\/j.talanta.2025.129132_bib576","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.eururo.2018.07.038","article-title":"Health economic analysis of open and robot-assisted laparoscopic surgery for prostate cancer within the prospective multicentre LAPPRO trial","volume":"74","author":"Forsmark","year":"2018","journal-title":"Eur. Urol."},{"key":"10.1016\/j.talanta.2025.129132_bib577","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jval.2015.12.019","article-title":"A multidimensional analysis of prostate surgery costs in the United States: robotic-assisted versus retropubic radical prostatectomy","volume":"19","author":"Bijlani","year":"2016","journal-title":"Value Health"},{"key":"10.1016\/j.talanta.2025.129132_bib578","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-058394","article-title":"Systematic literature review of cost-effectiveness analyses of robotic-assisted radical prostatectomy for localised prostate cancer","volume":"12","author":"Song","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.talanta.2025.129132_bib579","article-title":"Cost-analysis of robot-assisted radical cystectomy in Europe: a cross-country comparison","author":"Mjaess","year":"2022","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.talanta.2025.129132_bib580","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/bjs5.50235","article-title":"Systematic review of learning curves in robot-assisted surgery","volume":"4","author":"Soomro","year":"2020","journal-title":"BJS Open"},{"key":"10.1016\/j.talanta.2025.129132_bib581","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11934-021-01062-w","article-title":"Integration of robotics in urology residency programs: an unchecked technological revolution","volume":"22","author":"Hague","year":"2021","journal-title":"Curr. Urol. Rep."},{"key":"10.1016\/j.talanta.2025.129132_bib582","article-title":"Assessment of the training program for versius, a new innovative robotic system for use in minimal access surgery","volume":"18","author":"Butterworth","year":"2021","journal-title":"BMJ Surg. Interv. Health Technol."},{"key":"10.1016\/j.talanta.2025.129132_bib583","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1089\/lap.2020.0822","article-title":"Comparison of the learning curve for robot-assisted laparoscopic pyeloplasty between senior and junior surgeons","volume":"31","author":"Spampinato","year":"2021","journal-title":"J. Laparoendosc. Adv. Surg. Technol."},{"key":"10.1016\/j.talanta.2025.129132_bib584","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1089\/end.2021.0388","article-title":"Systematic review: the learning curve for robot-assisted radical cystectomy\u2014what do we know?","volume":"36","author":"Morozov","year":"2022","journal-title":"J. Endourol."},{"key":"10.1016\/j.talanta.2025.129132_bib585","doi-asserted-by":"crossref","DOI":"10.1177\/17562872221128791","article-title":"A review of artificial intelligence in prostate cancer detection on imaging","volume":"14","author":"Bhattacharya","year":"2022","journal-title":"Therapeutic advances in urology"},{"key":"10.1016\/j.talanta.2025.129132_bib586","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s11263-015-0816-y","article-title":"ImageNet large scale visual recognition challenge","volume":"115","author":"Russakovsky","year":"2015","journal-title":"Int J Comput Vision"},{"key":"10.1016\/j.talanta.2025.129132_bib587","series-title":"International Conference on Medical Image Computing and computer-assisted Intervention","first-page":"506","article-title":"Inter-site variability in prostate segmentation accuracy using deep learning","author":"Gibson","year":"2018"},{"key":"10.1016\/j.talanta.2025.129132_bib588","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-69250-1","article-title":"Federated learning in medicine: facilitating multi-institutional collaborations without sharing patient data","volume":"10","author":"Sheller","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.talanta.2025.129132_bib589","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41746-020-00323-1","article-title":"The future of digital health with federated learning","volume":"3","author":"Rieke","year":"2020","journal-title":"npj Digit. Med."},{"key":"10.1016\/j.talanta.2025.129132_bib590","series-title":"International MICCAI Brainlesion Workshop","first-page":"92","article-title":"Multi institutional deep learning modeling without sharing patient data: a feasibility study on brain tumor segmentation","author":"Sheller","year":"2019"},{"key":"10.1016\/j.talanta.2025.129132_bib591","doi-asserted-by":"crossref","first-page":"903","DOI":"10.2214\/AJR.19.22573","article-title":"Multicenter multireader evaluation of an artificial intelligence-based attention mapping system for the detection of prostate cancer with multiparametric MRI","volume":"215","author":"Mehralivand","year":"2020","journal-title":"Am. J. Roentgenol."},{"key":"10.1016\/j.talanta.2025.129132_bib592","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S1470-2045(19)30738-7","article-title":"Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population based, diagnostic study","volume":"21","author":"Str\u00f6m","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.talanta.2025.129132_bib593","author":"Bulten"},{"key":"10.1016\/j.talanta.2025.129132_bib594","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1038\/s41379-020-0551-y","article-title":"Novel artificial intelligence system increases the detection of prostate cancer in whole slide images of core needle biopsies","volume":"33","author":"Raciti","year":"2020","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.talanta.2025.129132_bib595","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.23267","article-title":"Evaluation of the use of combined artificial intelligence and pathologist assessment to review and grade prostate biopsies","volume":"3","author":"Steiner","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.talanta.2025.129132_bib596","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.26100","article-title":"Can computer-aided diagnosis assist in the identification of prostate cancer on prostate MRI? A multi-center, multi-reader investigation","volume":"9","author":"Gaur","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.talanta.2025.129132_bib597","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1097\/JU.0000000000001783","article-title":"Deep learning improves speed and accuracy of prostate gland segmentations on magnetic resonance imaging for targeted biopsy","volume":"206","author":"Soerensen","year":"2021","journal-title":"J. Urol."},{"key":"10.1016\/j.talanta.2025.129132_bib598","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41591-021-01620-2","article-title":"Artificial intelligence for diagnosis and Gleason grading of prostate cancer: the panda challenge","volume":"28","author":"Bulten","year":"2022","journal-title":"Nat Med"}],"container-title":["Talanta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039914025016236?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039914025016236?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T08:40:27Z","timestamp":1781253627000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039914025016236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":592,"alternative-id":["S0039914025016236"],"URL":"https:\/\/doi.org\/10.1016\/j.talanta.2025.129132","relation":{},"ISSN":["0039-9140"],"issn-type":[{"value":"0039-9140","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular targeted therapies, omics, and AI based theranostics approaches for the treatment of prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Talanta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.talanta.2025.129132","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"129132"}}